Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 56
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Profiling TREM2 expression in amyotrophic lateral sclerosis

  • Jericó-Pascual, Ivonne|||0000-0003-4262-6370
  • Vicuña-Urriza, J.
  • Blanco-Luquin, I.
  • Macias, M.
  • Martinez-Merino, L.
  • Roldán, M.
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Pagola-Lorz, Inma
  • Carbayo Viejo, Álvaro|||0000-0001-9282-8603
  • Luna Salva, Noemí de|||0000-0002-4342-794X
  • Zelaya, V.
  • Mendioroz, Maite|||0000-0002-4179-5781
There is growing evidence of the contribution of neuroinflammation, and in particular microglia, in the pathogenesis of amyotrophic lateral sclerosis (ALS). TREM2 gene plays a crucial role in shaping microglia in neurodegenerative conditions. To deepen the understanding of TREM2 in ALS and investigate the performance of TREM2 as a biomarker, we profiled TREM2 expression levels in spinal cord, cerebrospinal fluid and blood of patients with sporadic ALS. We also wanted to investigate whether the combined measurement of sTREM2 in fluids could improve the diagnostic yield of total and phosphorylated TDP-43 levels. We performed a case-control study to profile overall and transcript-specific TREM2 mRNA levels by RT-qPCR and protein expression levels by Western-blot in postmortem specimens of spinal cord from ALS patients and controls. In parallel, we measured soluble TREM2 (sTREM2) protein levels and full length and phosphorylated TDP-43 (tTDP-43 and pTDP-43) by ELISA in CSF and serum from ALS patients vs healthy controls. Patients were prospectively recruited from an ALS unit of a tertiary hospital and fulfilled El Escorial revised criteria. After bivariate analysis, a logistic regression model was developed to identify adjusted estimates of the association of sTREM2 levels in CSF and serum with ALS status. Overall and transcript-specific TREM2 mRNA were upregulated in the spinal cord of ALS patients (n = 21) compared to controls (n = 19). Similar changes were observed in TREM2 protein levels (p < 0.01) in spinal cord of ALS patients vs healthy controls. We also detected significantly higher sTREM2 levels in CSF (p-value < 0.01) of ALS patients (n = 46) vs controls (n = 46) and serum (p-value < 0.001) of ALS patients (n = 100) vs controls (n = 100). In a logistic regression model, both CSF and serum sTREM2 remained independently associated with ALS status with OR = 3.41 (CI 95 %=1.34-8.66) (p-value < 0.05) and OR = 3.38 (CI 95 %: 1.86-6.16) (p-value < 0.001), respectively. We also observed that pTDP-43 levels in CSF is an independent predictor of ALS (p-value < 0.05). Our results support the role of TREM2 in ALS pathophysiology and demonstrates that the three TREM2 transcripts are deregulated in ALS in postmortem human specimens of spinal cord. We hypothesise about the possible influence of systemic-peripheral inflammation in the disease. Finally, we conclude that pTDP-43 levels in CSF could be a biomarker of ALS, and sTREM2 measurement in CSF and blood emerge as potential non-invasive biomarker in ALS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Atherogenic circulating lipoproteins in ischemic stroke

  • Benitez, Sonia|||0000-0003-3565-0743
  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Camps-Renom, Pol|||0000-0001-6587-6271
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
The fundamental role of qualitative alterations of lipoproteins in the early development of atherosclerosis has been widely demonstrated. Modified low-density lipoproteins (LDL), such as oxidized LDL (oxLDL), small dense LDL (sdLDL), and electronegative LDL [LDL(-)], are capable of triggering the atherogenic process, favoring the subendothelial accumulation of cholesterol and promoting inflammatory, proliferative, and apoptotic processes characteristic of atherosclerotic lesions. In contrast, high-density lipoprotein (HDL) prevents and/or reverses these atherogenic effects. However, LDL's atherogenic and HDL's anti-atherogenic actions may result altered in certain pathological conditions. The molecular mechanisms underlying the impaired effects of altered lipoproteins have been studied in numerous in vitro and in vivo studies, and have been extensively analyzed in coronary atherosclerosis, especially in the context of pathologies such as dyslipidemia, diabetes, obesity, and metabolic syndrome. However, the corresponding studies are scarcer in the field of ischemic stroke, despite carotid arteriosclerosis progression underlies at least 20% of ischemic strokes. The present review relates qualitative alterations of LDL and HDL with the development of carotid arteriosclerosis and the occurrence of ischemic stroke.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

The transition to motherhood, linking hormones, brain and behaviour

  • Servin-Barthet, Camila|||0000-0002-4771-898X
  • Martínez-García, Magdalena|||0000-0002-5054-9427
  • Pretus, Clara|||0000-0003-2172-1184
  • Paternina-Die, María|||0000-0002-5100-4955
  • Soler Campillo, Anna
  • Khymenets, Olha|||0000-0002-8668-580X
  • Pozo, Oscar J.|||0000-0002-1735-9728
  • Leuner, Benedetta|||0000-0002-8919-6892
  • Vilarroya Oliver, Óscar|||0000-0001-8285-5624
  • Carmona Cañabate, Susana|||0000-0001-5853-6527
We are witnessing a stark increase in scientific interest in the neurobiological processes associated with pregnancy and maternity. Convergent evidence suggests that around the time of labour, first-time mothers experience a specific pattern of neuroanatomical changes that are associated with maternal behaviour. Here we provide an overview of the human neurobiological adaptations of motherhood, focusing on the interplay between pregnancy-related steroid and peptide hormones, and neuroplasticity in the brain. We discuss which brain plasticity mechanisms might underlie the structural changes detected by MRI, which hormonal systems are likely to contribute to such neuroanatomical changes and how these brain mechanisms may be linked to maternal behaviour. This Review offers an overarching framework that can serve as a roadmap for future investigations.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Citizen Science to Raise Antimicrobial Resistance Awareness in the Community, The Project in Spain and Portugal

  • Gil-Serna, Jessica
  • Antunes, Patricia
  • Campoy Sánchez, Susana|||0000-0003-1369-0197
  • Cid, Ángeles|||0000-0002-0111-2122
  • Cobo-Molinos, Antonio
  • Durão, Paulo
  • Fajardo-Montañana, Carmen|||0000-0002-0784-0761
  • Fouz, Belén
  • Freitas, Ana R.|||0000-0002-7326-4133
  • Grosso, Filipa
  • de Groot, Piet W. J.
  • de Miguel, Trinidad
  • Zorn, Bruno González
  • Hinojosa, Belén
  • Leão, Maria João
  • Llagostera Casas, Montserrat|||0000-0001-8177-8321
  • de Llanos, Rosa
  • Lucía, Ainhoa
  • Maicas, Sergi
  • Marín, Irma
  • Martínez-Cañamero, Magdalena
  • Miranda, Carla
  • Molina-Guijarro, José Manuel|||0000-0003-4013-7792
  • Moreno, Diego A.|||0000-0002-6547-8764
  • de los Llanos Palop, María
  • Pérez-Álvarez, María José|||0000-0002-1978-4867
  • Pereira, Pedro M.
  • Pérez-Gracia, María Teresa
  • Quinteira, Sandra
  • Rioboo, Carmen
  • Robredo, Beatriz
  • Rodríguez-Calleja, José María
  • de la Haba, Rafael R.|||0000-0002-4615-780X
  • Sánchez Poza, Sandra|||0000-0001-9601-3866
  • Sánchez Angulo, Manuel|||0000-0002-4200-3117
  • Sánchez-Porro, Cristina
  • Sangari, Félix J.
  • Santos, Beatriz
  • Silveira, Eduarda|||0000-0001-6760-0148
  • Vicedo, Begonya
  • Cid, Víctor J.|||0000-0002-3933-2016
Antimicrobial resistance (AMR) poses a global threat to human, animal and environmental health. Among the multidisciplinary tasks aimed at collectively tackling the AMR crisis, surveillance, research and education stand as major priorities. Based on a crowdsourcing research strategy, the MicroMundo project, a partner of the Tiny Earth initiative in Spain and Portugal, has been developed and consolidated with success in the academic environment. The objectives are focused on promoting research and, especially, on bringing knowledge of One Health and microbiology concepts, as well as AMR awareness to the community. Following a service-learning approach, MicroMundo integrates university and secondary/high school students in a citizen science-based research project to collectively isolate microorganisms with the potential to produce new antibiotics from soil environments. Over the last 7 years, 32 MicroMundo hubs operating across 31 different Portuguese and Spanish universities have recruited thousands of teenagers in this quest. Here we review the outcome of this unprecedented effort from a scientific and an educational perspective.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

When should the nephrologist think about genetics in patients with glomerular diseases?

  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Barros, Xoana|||0000-0001-9690-9769
  • Díaz Encarnación, Montserrat Mercedes|||0000-0001-5172-3370
  • Fayos de Arizón, Leonor|||0000-0002-9277-645X
  • Furlano, Monica|||0000-0003-1025-3901
  • Pilco-Teran, Melissa|||0000-0002-1311-0896
  • Pybus, Marc|||0000-0002-6195-5738
  • Shabaka, Amir|||0000-0001-7039-4701
  • Viera, Elizabeth|||0000-0002-3548-7061
  • Ars, Elisabet|||0000-0002-4118-4358
This review discusses the significance of genetics in diagnosing glomerular diseases. Advances in genetic testing, particularly next-generation sequencing, have improved the accessibility and accuracy of diagnosing monogenic diseases, allowing for targeted gene panels and whole-exome/genome sequencing to identify genetic variants associated with glomerular diseases. Key indicators for considering a genetic cause include the age of onset, extrarenal features, family history, and inconclusive kidney biopsy results. Early-onset diseases, for instance, have a higher likelihood of being genetically caused, while extrarenal manifestations can also suggest an underlying genetic condition. A thorough family history can reveal patterns of inheritance that point to monogenic causes, although complexities like incomplete penetrance, skewed X inactivation and mosaicism can complicate the assessment. Also, autosomal recessive conditions imply asymptomatic parents, making genetic suspicion less likely, while de novo mutations can occur without any family history, further obscuring genetic assessment. Focal segmental glomerulosclerosis (FSGS) is characterized by podocyte injury and depletion, presenting in various forms, including primary, genetic, and secondary FSGS. Accurate classification of FSGS patients based on clinical and histological features is essential for guiding treatment decisions, optimizing therapeutic plans, avoiding unnecessary immunosuppression, and predicting relapse risk after kidney transplantation. Overall, a clinicopathological approach, enriched by genetic testing, offers a precise framework for diagnosis and management in glomerular diseases. Future directions for research and clinical practice include potential advancements in genetic testing and personalized medicine, which could further improve diagnostic precision and individualized treatment strategies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Nanotoxin induces in situ pyroptosis to sensitize αPD1 to ablate metastases in microsattellite stable colorectal cancer

  • Carrasco-Díaz, Luis Miguel|||0000-0003-0567-2802
  • Otero-Mateo, Marc
  • Álamo, Patricia|||0000-0003-0510-5701
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Virgili Manrique, Anna Cristina|||0000-0001-9733-6034
  • Paez, David|||0000-0002-5596-6588
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Mangues, Ramon|||0000-0003-2661-9525
Nanomedicine has not generated anticancer immunotherapies because of insufficient targeted specificity, lack of immunity, and associated toxicity. We developed a T22-DITOX-H6 (TDX) nanotoxin to selectively release the diphtheria toxin in the cancer cells in immunosuppressed CXCR4-overexpressing (CXCR4 +) colorectal (CRC) models, inducing pyroptosis and anticancer effect. Microsatellite stable (MSS) CRC patients do not respond to current immunotherapy. Since pyroptosis is highly immunogenic, we treated with TDX immunocompetent CXCR4 + CT26 MSS metastatic CRC models to selectively deliver the toxin to induce in situ pyroptosis mediated by the activation of NLRP3, Caspase-1 GSDMD and IL-1β. In contrast to immunosuppressed, in situ pyroptosis by TDX in immunocompetent models trigger CD8 + T cell recruitment, activation and killing of cancer cells in tissues, mimicking the pyroptosis that the host induces to kill diphtheria-infected cells. The combination of TDX and αPD1 further increases CD8 + recruitment and perforin secretion, achieving a tissue-specific antimetastatic activity in mesentery, peritoneum, and lung, and especially in liver metastases, without systemic toxicity. This is the first time that a novel nanomedicine achieves local T cell activation and antimetastatic effect mediated by pyroptosis and immunogenic cell death, whereas the combination with αPD1 enhances T cell activation, reaching a synergistic response in MSS CRC models.
Repisalud
Publicación Artículo de revisión (ReviewArticle)

Diagnostic performance of dried blood spot hepatitis C virus core antigen testing for hepatitis C screening: A systematic review and meta-analysis.

  • Treviño-Nakoura, Ana
  • Sepulveda-Crespo, Daniel
  • Bellon, José M
  • Codina, Helena
  • Amigot-Sánchez, Rafael
  • Quero-Delgado, Marta
  • Ryan, Pablo
  • Martinez, Isidoro
  • Resino, Salvador
Dried blood spot (DBS) sampling is increasingly used for hepatitis C virus (HCV) screening. HCVcAg testing offers a faster and more streamlined approach to diagnosing HCV infection. We conducted a systematic review and meta-analysis to assess the diagnostic performance of the Abbott ARCHITECT HCV Ag assay for screening active HCV infection using DBS samples. Eight studies (n = 1229) were selected among all published studies available up to October 4, 2024, in different databases with a search strategy registered (PROSPERO: CRD42022363975). The gold standard method was the HCV PCR test. Data were analyzed using the MIDAS module in STATA with a random effects model. Combined diagnostic accuracy measures were as follows: sensitivity 85%, specificity 100%, positive likelihood ratio (PLR) 233.1, negative likelihood ratio (NLR) 0.15, and summary receiver operating characteristic (SROC) 0.99. Likelihood ratios and Fagan's nomogram suggested that the HCVcAg assay with DBS samples can confirm or rule out active HCV infection with over 92% accuracy in high-prevalence settings (≥5%). However, in low-prevalence settings (≤1%), a confirmatory test must be required for positive results. The ability of the test to identify people without HCV infection was high regardless of HCV prevalence, with an error rate of less than 3%. This meta-analysis is subject to limitations, particularly due to the number of included studies and significant heterogeneity among them. HCV screening using the Abbott ARCHITECT HCV Ag assay with DBS samples showed excellent diagnostic performance, but its external validity may be limited when HCV prevalence is low (≤1%).
Repisalud
Publicación Artículo de revisión (ReviewArticle)

Advances in Nanotechnology-Enabled Optical Biosensors for Dengue Virus Detection: A Systematic Review.

  • Quero-Delgado, Marta
  • Codina Márquez, Helena
  • Gómez, Rafael
  • Terán, Francisco José
  • Muñoz-Fernández, M A
  • Jiménez, José Luis
  • Resino, Salvador
  • Sepulveda-Crespo, Daniel
  • Martinez, Isidoro
The dramatic surge in dengue cases in early 2024, endangering half the global population, urgently necessitates faster diagnostic methods. Nanotechnology-enabled optical biosensors offer a promising avenue, leveraging nanomaterial properties for highly sensitive detection of dengue virus (DENV), potentially surpassing conventional techniques in terms of simplicity, speed, and cost-effectiveness. This systematic review analyzes recent advancements in these biosensors for DENV diagnosis. Following PRISMA 2020 guidelines, we systematically searched PubMed, Embase, Scopus, Web of Science, and Cochrane Library databases (2010-June 1, 2025; OSF: https://osf.io/3gmey/). The methodological quality of the 98 included studies was assessed using a modified CASP checklist. Diverse nanotechnology-based optical biosensors were identified. SPR (36.7%) was the most common transducer, followed by fluorescence (24.5%), colorimetry (15.3%), and SERS (8.2%). Gold-based nanomaterials (35.7%) were most frequently employed, with silver nanomaterials (15.3%), quantum dots (15.3%), and graphene-based materials (15.3%) also showing promise. DENV NS1 protein was the primary target analyte (21.4%). Importantly, almost half of the studies (44.9%) used clinically relevant human samples. While many optical biosensors show promise, challenges hinder their demonstration of the true potential for point-of-care use in their current format; however, they offer high specificity and faster results, laying a strong foundation for cost-effective clinical diagnostics. Nanotechnology-driven optical biosensors offer a transformative approach for DENV detection. Advances in computational design and green synthesis of novel nanomaterials are key to addressing stability and field-deployment challenges. These innovations are crucial for developing robust, sensitive, and user-friendly tools to manage dengue and improve patient outcomes globally.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo de revisión (ReviewArticle)

Measurement of energy resolution with the NEXT-White silicon photomultipliers

  • Contreras, T.
  • Palmeiro, B.
  • Almazán, H.
  • Para, A.
  • Martinez-Lema, G.
  • Guenette, R.
  • Adams, C.
  • Aparicio, B.
  • Aranburu, A. I.
  • Arazi, L.
  • Arnquist, I.J.
  • Auria-Luna, F.
  • Ayet, S.
  • Azevedo, C.D.R.
  • Álvarez-Puerta, Vicente|||0000-0001-6938-8259
  • Ballester Merelo, Francisco José|||0000-0002-2464-5116
  • Esteve Bosch, Raul|||0000-0002-1289-6938
  • Herrero Bosch, Vicente|||0000-0003-0860-2789
  • Mora Mas, Francisco José|||0000-0003-2281-9546
  • Toledo Alarcón, José Francisco|||0000-0002-9782-4510
[EN] The NEXT-White detector, a high-pressure gaseous xenon time projection chamber, demonstrated the excellence of this technology for future neutrinoless double beta decay searches using photomultiplier tubes (PMTs) to measure energy and silicon photomultipliers (SiPMs) to extract topology information. This analysis uses 83mKr data from the NEXT-White detector to measure and understand the energy resolution that can be obtained with the SiPMs, rather than with PMTs. The energy resolution obtained of (10.9±0.6)%, full-width half-maximum, is slightly larger than predicted based on the photon statistics resulting from very low light detection coverage of the SiPM plane in the NEXT-White detector. The difference in the predicted and measured resolution is attributed to poor corrections, which are expected to be improved with larger statistics. Furthermore, the JHEP09(2024)112 noise of the SiPMs is shown to not be a dominant factor in the energy resolution and may be negligible when noise subtraction is applied appropriately, for high-energy events or larger SiPM coverage detectors. These results, which are extrapolated to estimate the response of large coverage SiPM planes, are promising for the development of future, SiPM-only, readout planes that can offer imaging and achieve similar energy resolution to that previously demonstrated with PMTs., The NEXT Collaboration acknowledges support from the following agencies and institutions: the European Research Council (ERC) under Grant Agreement No. 951281-BOLD; the European Union’s Framework Programme for Research and Innovation, Horizon 2020 (2014–2020), under Grant Agreement No. 957202-HIDDEN; Spain’s MCIN/AEI and the ERDF (“A way of making Europe”) under grants PID2021-125475NB and the Severo Ochoa Programme grant CEX2018-000867-S; the Generalitat Valenciana (Spain) under grants PROMETEO/2021/087 and CIDEGENT/2019/049; the Department of Education of the Basque Government (Spain) under the predoctoral training programme for non-doctoral research personnel; the “la Caixa” Foundation (ID 100010434) under fellowship code LCF/BQ/PI22/11910019; the Portuguese Foundation for Science and Technology (FCT) under project UID/FIS/04559/2020 supporting the activities of LIBPhys-UC; the Israel Science Foundation (ISF) under grant 1223/21; the Pazy Foundation (Israel) under grants 310/22, 315/19, and 465; the U.S. Department of Energy under contract numbers DE-AC02-06CH11357 (Argonne National Laboratory), DE-AC02-07CH11359 (Fermi National Accelerator Laboratory), DE-FG02-13ER42020 (Texas A&M), DE-SC0019054 (The University of Texas at Arlington), and DE-SC0019223 (The University of Texas at Arlington); the U.S. National Science Foundation under award NSF CHE-2004111; and the Robert A. Welch Foundation under award Y-2031-20200401. Finally, we are grateful to the Laboratorio Subterráneo de Canfranc for hosting and supporting the NEXT experiment.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Transcranial direct current stimulation combined with robotic therapy for upper and lower limb function after stroke: a systematic review and meta-analysis of randomized control trials

  • Comino-Suárez, Natalia
  • Moreno, Juan Camilo
  • Gómez-Soriano, Julio
  • Megía-García, Á.
  • Serrano-Muñoz, D.
  • Taylor, Julian S.
  • Alcobendas-Maestro, M.
  • Gil-Agudo, Ángel
  • Ama, Antonio J. del
  • Avendaño-Coy, J.
Background: Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation method able to modulate neuronal activity after stroke. The aim of this systematic review was to determine if tDCS combined with robotic therapy (RT) improves limb function after stroke when compared to RT alone. Methods: A search for randomized controlled trials (RCTs) published prior to July 15, 2021 was performed. The main outcome was function assessed with the Fugl-Meyer motor assessment for upper extremities (FM/ue) and 10-m walking test (10MWT) for the lower limbs. As secondary outcomes, strength was assessed with the Motricity Index (MI) or Medical Research Council scale (MRC), spasticity with the modified Ashworth scale (MAS), functional independence with the Barthel Index (BI), and kinematic parameters. Results: Ten studies were included for analysis (n = 368 enrolled participants). The results showed a non-significant effect for tDCS combined with RT to improve upper limb function [standardized mean difference (SMD) = − 0.12; 95% confidence interval (CI): − 0.35–0.11)]. However, a positive effect of the combined therapy was observed in the lower limb function (SMD = 0.48; 95% CI: − 0.15–1.12). Significant results favouring tDCS combined with RT were not found in strength (SMD = − 0.15; 95% CI: − 0.4–0.1), spasticity [mean difference (MD) = − 0.15; 95% CI: − 0.8–0.5)], functional independence (MD = 2.5; 95% CI: − 1.9–6.9) or velocity of movement (SMD = 0.06; 95% CI: − 0.3–0.5) with a “moderate” or “low” recommendation level according to the GRADE guidelines. Conclusions: Current findings suggest that tDCS combined with RT does not improve upper limb function, strength, spasticity, functional independence or velocity of movement after stroke. However, tDCS may enhance the effects of RT alone for lower limb function. tDCS parameters and the stage or type of stroke injury could be crucial factors that determine the effectiveness of this therapy., This was supported by the Ministerio de Economía, Industria y Competitividad. RECODE project [Grant number: DPI2017‑91117‑EXP]; and by Junta de Comunidades de Castilla la Mancha and Fondo Europeo de Desarrollo Regional (Fondos FEDER). EXO‑STIM Project [Grant number: SBPLY/19/180501/000316].
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Emerging pharmacological treatment options for MAFLD

  • Rojas, Ángela
  • Lara-Romero, Carmen
  • Muñoz-Hernández, Rocío
  • Gato, Sheila
  • Ampuero, Javier
  • Romero-Gómez, Manuel
Metabolic dysfunction–associated fatty liver disease (MAFLD) prevalence and incidence is rising globally. It is associated with metabolic comorbidities, obesity, overweight, type 2 diabetes mellitus, and at least two metabolic risk factors, such as hypertension, hypertriglyceridemia, hypercholesterolemia, insulin resistance, and cardiovascular risk, increasing the risk of mortality. The excessive accumulation of fat comprises apoptosis, necrosis, inflammation and ballooning degeneration progressing to fibrosis, cirrhosis, and liver decompensations including hepatocellular carcinoma development. The limitation of approved drugs to prevent MAFLD progression is a paradigm. This review focuses on recent pathways and targets with evidence results in phase II/III clinical trials., Ministerio de Ciencia y Competitividad under grant agreements PI19/01404 and PI19/00589. A contract with fellowship from Consejería de Salud y Familias, Junta de Andalucía, supporting Angela Rojas (RH-002-2021); grant agreements PFIS FI20/00201 from Instituto de Salud Carlos III to support Sheila Gato and by support from Talento Doctores (PID Junta Andalucía, DOC_00866) to Rocío Muñoz-Hernández., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Glutaminolysis-ammonia-urea Cycle Axis, Non-alcoholic Fatty Liver Disease Progression and Development of Novel Therapies

  • Rojas, Ángela
  • García-Lozano, María del Rosario
  • Gil-Gómez, Antonio
  • Romero-Gómez, Manuel
  • Ampuero, Javier
The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing worldwide, reflecting the current epidemics of obesity, insulin resistance, type 2 diabetes mellitus, and metabolic syndrome. NAFLD is characterized by the accumulation of fat in the liver, and is known to be a cause of cirrhosis. Although many pathways have been proposed, the cause of NAFLD-linked fibrosis progression is still unclear, which posed challenges for the development of new therapies to prevent NASH-related cirrhosis and hepatocellular carcinoma. Cirrhosis is associated with activation of hepatic stellate cells (HSC) and accumulation of excess extracellular matrix proteins, and inhibiting the activation of HSCs would be expected to slow the progression of NAFLD-cirrhosis. Multiple molecular signals and pathways such as oxidative stress and glutaminolysis have been reported to promote HSC activation. Both mechanisms are plausible antifibrotic targets in NASH, as the activation of HSCs the proliferation of myofibroblasts depend on those processes. This review summarizes the role of the glutaminolysis-ammonia-urea cycle axis in the context of NAFLD progression, and shows how the axis could be a novel therapeutic target., This project was funded in part by the Spanish Ministry of Economy, Innovation and Competition, Instituto de Salud Carlos III (PI19/00589, PI19/01404, PI16/01842, PI17/00535 and GLD19/00100). Ángela Rojas has received the Sara Borrell postdoctoral fellowships from Instituto de Salud Carlos III CD18/00126 to support her postdoctoral contract., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Corticospinal adaptations following resistance training and its relationship with strength: A systematic review and multivariate meta-analysis

  • Gómez-Feria, José
  • Martín-Rodríguez, Juan Francisco
  • Mir, Pablo
© 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/)., Neural adaptations to resistance training (RT) and their correlation with muscle strength remain partially understood. We conducted a systematic review and multivariate meta-analysis to examine the effects of metronome-paced (MP), self-paced (SP), and isometric (IM) training on M1 and corticospinal pathway activity. Following MP RT, a significant increase in corticospinal excitability was observed, correlating with increased strength. Conversely, no significant relationship was found after SP or IM training. RT also reduced the duration of the cortical silent period, but this change did not predict strength changes and was not specific to any training modality. No significant effects were found for short-interval intracortical inhibition. Our findings suggest that changes in corticospinal excitability may contribute to strength gains after RT. Furthermore, the relationship between these adaptations and strength appears dependent on the type of training performed., This work was supported by the Spanish Ministry of Science and Innovation [RTC2019-007150-1], the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) [PI14/01823, PI16/01575, PI18/01898, PI19/01576, PI21/01875, PI22/01704], the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019], the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía [PY20_00896], and the Fundación Alicia Koplowitz. JG-F is supported by the Ministerio de Ciencia e Innovación (Grant FPU16/03550). JFM-R is supported by VI-PPIT-US from the University of Seville (USE-18817-A)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Risk of suicide attempt repetition after an index attempt: A systematic review and meta-analysis

  • Torre-Luque, Alejandro de la
  • Pemau, Andres
  • Ayad-Ahmed, Wala
  • Borges, Guilherme
  • Fernández-Sevillano, Jessica
  • Garrido-Torres, Nathalia
  • Garrido-Sánchez, Lucia
  • Garriga, Marina
  • González-Ortega, Itxaso
  • González-Pinto, Ana
  • Grande, Iria
  • Guinovart, Marti
  • Hernandez-Calle, Daniel
  • Jiménez-Treviño, Luis
  • López-Sola, Clara
  • Mediavilla, Roberto
  • Pérez-Aranda, Adrián
  • Ruiz‐Veguilla, Miguel
  • Seijo-Zazo, Elisa
  • Toll, Alba
  • Pérez-Sola, Víctor
  • Ayuso-Mateos, José Luis
  • SURVIVE Consortium
© 2023 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/)., [Objectives] To estimate the risk of suicide attempt repetition among individuals with an index attempt. It also aims to study the role of risk factors and prevention programme in repetition., [Methods] This systematic review and meta-analysis was conducted in keeping with the PRISMA 2020 guidelines. Studies on attempt repetition (both cohort studies and intervention studies) were searched from inception to 2022., [Results] A total of 110 studies comprising 248,829 attempters was reviewed. The overall repetition rate was 0.20 (0.17, 0.22). Repetition risk linearly increased over time. A higher risk of attempt repetition was associated with female sex and index attempts in which self-cutting methods were used. Moreover, a mental disorder diagnosis was associated with an increasing repetition risk (OR = 2.02, p < .01). The delivery of a preventive programme reduced the repetition risk, OR = 0.76, p < .05; however, this effect was significant for psychotherapy interventions, OR = 0.38, p < .01., [Conclusion] One in five suicide attempters will engage in a new suicide attempt. An elevated repetition risk is associated with being female, more severe index methods and psychiatric disorder diagnosis. Preventive programmes, particularly psychotherapy, may contribute to reducing repetition risk and eventually save lives., This study was supported by the Instituto de Salud Carlos III-FIS research grants (PI16/00187, PI19/00236, PI19/00569, PI19/00685, PI19/00941, PI19/00954, PI19/01027, PI19/01256, PI19/01484, PI20/00229), co-funded by the European Regional Development Fund (ERDF) “A Way to Build Europe”; the Government of the Principality of Asturias (grant ref.: PCTI-2018-2022 IDI/2018/235); Secretaria d'Universitats i Recerca from the Departament d'Economia i Coneixement (ref.: 2017SGR1365 and 2017SGR134), and Generalitat de Catalunya (Government of Catalonia), CERCA Programme., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Radiogenomics in lung cancer: Where are we?

  • Aguado-Barrera, Miguel E.
  • Sosa-Fajardo, Paloma
  • Gómez-Caamaño, Antonio
  • Taboada-Valladares, Begoña
  • Couñago, Felipe
  • López-Guerra, José Luis
  • Vega, Ana I.
Huge technological and biomedical advances have improved the survival and quality of life of lung cancer patients treated with radiotherapy. However, during treatment planning, a probability that the patient will experience adverse effects is assumed. Radiotoxicity is a complex entity that is largely dose-dependent but also has important intrinsic factors. One of the most studied is the genetic variants that may be associated with susceptibility to the development of adverse effects of radiotherapy. This review aims to present the current status of radiogenomics in lung cancer, integrating results obtained in association studies of SNPs (single nucleotide polymorphisms) related to radiotherapy toxicities. We conclude that despite numerous publications in this field, methodologies and endpoints vary greatly, making comparisons between studies difficult. Analyzing SNPs from the candidate gene approach, together with the study in cohorts limited by the sample size, has complicated the possibility of having validated results. All this delays the incorporation of genetic biomarkers in predictive models for clinical application. Thus, from all analysed SNPs, only 12 have great potential as esophagitis genetic risk factors and deserve further exploration. This review highlights the efforts that have been made to date in the radiogenomic study of radiotoxicity in lung cancer., Contract grant sponsor Ana Vega: supported by Spanish Instituto de Salud Carlos III (ISCIII) funding, an initiative of the Spanish Ministry of Economy and Innovation partially supported by European Regional Development FEDER Funds [INT20/00071; PI19/01424]; the Autonomous Government of Galicia, Consolidation and structuring program [IN607B]; the Fundación Mutua Madrileña [MMA2018-1, 2018]; and the Asociación Española Contra el Cáncer (AECC) [PRYES211091VEGA, 2021]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mitochondrial Dysfunction and Mitophagy in Type 2 Diabetes: Pathophysiology and Therapeutic Targets

  • Apostolova, Nadezda
  • Vezza, Teresa
  • Muntané, Jordi
  • Rocha, Milagros
  • Victor, Víctor M.
Significance: Type 2 diabetes mellitus, which is related to oxidative stress and mitochondrial dysfunction, is one of the most prevalent diseases in the world. In the past decade, alterations in autophagy have been shown to play a fundamental role in the development and control of type 2 diabetes. Further, mitophagy has been recognized as a key player in eliminating dysfunctional mitochondria in this disease. Recent Advances: Recently, much progress has been made in understanding the molecular events associated with oxidative stress, mitochondrial dysfunction, and alterations in autophagy and mitophagy in type 2 diabetes. Critical Issues: Despite increasing evidence of a relationship between mitochondrial dysfunction, oxidative stress, and alterations of autophagy and mitophagy and their role in the pathophysiolology of type 2 diabetes, effective therapeutic strategies to combat the disease through targeting mitochondria, autophagy, and mitophagy are yet to be implemented. Future Directions: This review provides a wide perspective of the existing literature concerning the complicated interplay between autophagy, mitophagy, and mitochondrial dysfunction in type 2 diabetes. Further, potential therapeutic targets based on these molecular mechanisms are explored. Antioxid. Redox Signal. 39, 278–320., This research was supported by the European Regional Development Fund (ERDF “A way to build Europe”); FISABIO (Foundation for the Promotion of Health and Biomedical Research in the Valencian Region, grants UGP15-220 and UGP-21-236); Generalitat Valenciana (grants PROMETEO/2019/027 and AICO/2021/017); and Spanish Ministry of Science and Innovation (grants CIBERehd CB06/04/0071, PI22/00424, PI22/1009, PI19/0437, and PI19/00838 from Carlos III Health Institute, and grant PID2021-127945OB-I00 funded by MCIN/AEI/10.13.039/501100011033/and by FEDER)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Antifibrotic Agents for the Management of CKD: A Review

  • Ruiz-Ortega, Marta
  • Lamas Peláez, Santiago
  • Ortiz, Alberto
Kidney fibrosis is a hallmark of chronic kidney disease (CKD) and a potential therapeutic target. However, there are conceptual and practical challenges to directly targeting kidney fibrosis. Whether fibrosis is mainly a cause or a consequence of CKD progression has been disputed. It is unclear whether specifically targeting fibrosis is feasible in clinical practice because most drugs that decrease fibrosis in preclinical models target additional and often multiple pathogenic pathways (eg, renin-angiotensin-aldosterone system blockade). Moreover, tools to assess whole-kidney fibrosis in routine clinical practice are lacking. Pirfenidone, a drug used for idiopathic pulmonary fibrosis, is undergoing a phase 2 trial for kidney fibrosis. Other drugs in use or being tested for idiopathic pulmonary fibrosis (eg, nintedanib, PRM-151, epigallocatechin gallate) are also potential candidates to treat kidney fibrosis. Novel therapeutic approaches may include antagomirs (eg, lademirsen) or drugs targeting interleukin 11 or NKD2 (WNT signaling pathway inhibitor). Reversing the dysfunctional tubular cell metabolism that leads to kidney fibrosis offers additional therapeutic opportunities. However, any future drug targeting fibrosis of the kidneys should demonstrate added benefit to a standard of care that combines renin-angiotensin system with mineralocorticoid receptor (eg, finerenone) blockade or with sodium/glucose cotransporter 2 inhibitors., This work was supported by grants from Instituto de Salud Carlos III (ISCIII) and Fondos FEDER European Union (PI17/00119, PI20/00140, DTS20/00083, PI18/01366, PI19/00588, PI19/00815, DTS18/00032, Red de Investigacion Renal REDINREN: RD16/0009, RICORS2040 RD21/0005/0001) Comunidad Autonoma de Madrid FEDER-a way to build Europe (B2017/ BMD-3751 NOVELREN-CM to MR-O and SL); Convocatoria Dinamizacion Europa Investigacion 2019 ” MINECO (EIN2019-103294 to M.R-O B2017/BMD-3686 CIFRA2-CM to AO); Innovation programme under the Marie Skłodowska-Curie grant of the European Union’s Horizon 2020 (IMPROVE-PD ID: 812699) to MR-O; and ERA-PerMed-JTC2018 (KIDNEY ATTACK AC18/00064 and PERSTIGAN AC18/00071, Sociedad Espanola de Nefrología, FRIAT, Comunidad de Madrid en Biomedicina and Ministerio de Ciencia e Innovación: PID2019-104233RB-I00/AEI/10.13039/501100011033 to SL
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Persistent elite controllers as the key model to identify permanent HIV remission

  • Gasca-Capote, Carmen
  • Ruiz-Mateos, Ezequiel
[Purpose of review] To summarize the heterogeneity in the elite controllers population with the aim to identify a compatible profile with a persistent HIV remission, making distinction between persistent elite controllers, people with HIV (PWHIV) who permanently maintain virological control in the absence of antiretroviral treatment (ART), and transient elite controllers, PWHIV who eventually lose virological control. For this purpose, it is important to consider the mechanisms and biomarkers that have previously been associated with the maintenance and loss of the natural virological control., [Recent findings] Transient elite controllers, before losing virological control, exhibit a distinct metabolomic, proteomic, microRNAs (miRNA), immunological and virological profile compared to persistent elite controllers. In addition to a reduced and less polyfunctional HIV-specific T-cell response, transient elite controllers show a greater proportion of intact proviruses integrated into genic regions. In contrast, persistent elite controllers display a privileged HIV-1 reservoir profile with absence of detected intact proviruses or low proportion of clonal intact proviruses preferentially integrated into genomic features associated with HIV-1 transcriptional repression., [Summary] According to previous studies, the comprehensive characterization of persistent elite controllers might be crucial to identify other PWHIV with this distinct profile as spontaneously cured., This work was supported by the Instituto de Salud Carlos III (Fondo Europeo de Desarrollo Regional, FEDER, “a way to make Europe”, research contracts FI19/00083 and MV20/00057 to C.G.C. and research projects PI19/01127 and PI22/01796 to E.R.M.) and Gilead Fellowships (GLD22/00147 to E.R.M.). E.R.M. was granted by the Spanish National Research Council (CSIC)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

"Recommendations for clinical study protocols for immune and inflammatory profiling in Parkinson's disease"

  • Muñoz-Delgado, Laura
  • Williams-Gray, Caroline H.
  • Garraux, Gaetan
  • Clemente, Diego
  • Öztop-Çakmak, Özgür
  • Greenland, Julia C.
  • Figueira, Inês
  • Machín-Díaz, Isabel
  • Pirovano, Elenamaria
  • Di Flora, Alessia
  • Tournerie, Clotilde
  • Papoutsopoulou, Stamatia
  • Ertan, Sibel
  • Mir, Pablo
  • Comi, Cristoforo
Growing evidence supports the importance of immune processes in Parkinson’s disease (PD). However, there is a need to improve the quality of observational clinical studies investigating the role of immunity in PD. In this context, an expert panel from the COST Action IMMUPARKNET (CA21117) aimed to develop guidance recommendations for conducting optimal immune profiling in PD. Firstly, criteria for inclusion and exclusion of participants, clinical data collection and participant stratification have been considered. Secondly, brain imaging of neuroinflammation has been reviewed. Finally, this review discusses sample collection, handling and storage of biological samples. In conclusion, this document aims to guide the scientific community in the optimal design of immune profiling studies in PD, so that we can generate robust and reliable data to advance our knowledge in this field., This publication is based upon work from COST Action CA21117, The role of IMMUnity in tackling PARKinson’s disease through a Translational NETwork [IMMUPARKNET], supported by COST (European Cooperation in Science and Technology) (www.cost.eu). Laura Muñoz-Delgado is financially supported by the “Juan Rodés” programme (JR23/00016) from the Instituto de Salud Carlos III and receives funding support from the Consejería de Salud y Consumo de la Junta de Andalucía (NEU-0005-2022). Caroline Williams-Grey receives financial support from the NIHR Cambridge Biomedical Research Centre (NIHR203312) and the Cambridge Centre for Parkinson-Plus, and grant funding from the UKRI Medical Research Council (MR/W029235/1), Cure Parkinson’s, Parkinson’s UK, and the Rosetrees Trust. Gaetan Garraux is supported by ‘Fonds Rahier’, University of Liège and Fonds de la Recherche Scientifique (F.R.S.-FNRS) de Belgique. Gaëtan Garraux has also received support for travel or honorarium from AbbVie, Eurogenerics and Zambon. Diego Clemente has received funding support from Instituto de Salud Carlos III (PI18/00357, PI21/00302, PI24/00447, co-funded by the European Union, CIBERNED CB22/05/00016, “INVESTIGO” programme in the frame of the Plan para la Recuperación, Transformación y Resiliencia (European Union Next Generation funds), and EMD Serono R&D Agreement). Ines Figueira is supported by the the ERC—Grant No. 804229; through PeX—2022.02127.PTDC (PERCEPT) and through the R&D unit iNOVA4Health (LISBOA-01-0145-FEDER-007344; UIDB/04462/2020), and LS4FUTURE Associated Laboratory (LA/P/0087/2020).Pablo Mir has received financial support from the Spanish Ministry of Science and Innovation (RTC2019-007150-1), the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) (PI16/01575, PI18/01898, PI19/01576, PI20/00613, PI21/01875, PI22/01704 and PI23/00512), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CVI-02526, CTS-7685), the Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI-0471-2013, PE-0210-2018, PI-0459-2018 and PE-0186-2019), the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía (PY20_00896). Pablo Mir has also received support for attending meetings and/or travel or honorarium for lecturing from Abbott, Allergan, AbbVie, Bial, Britannia, Italfarmaco, Merz, UCB, Teva and Zambon. Cristoforo Comi is supported by the AGING PROJECT—Department of Excellence—Università del Piemonte Orientale. Cristoforo Comi has received travel grants for meeting participation from Ecupharma, Bial and Novartis., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Bridging the gap between individual specialization and species persistence in mutualistic communities

  • Arroyo-Correa, Blanca
  • Bartomeus, Ignasi
  • Jordano, Pedro
  • Cagua, E. Fernando
  • Stouffer, Daniel B.
Mutualistic interactions among organisms are fundamental to the origin and maintenance of biodiversity. Yet, the study of community dynamics often relies on values averaged at the species level, ignoring how intraspecific variation can affect those dynamics. We developed a theoretical approach to evaluate the extent to which variation within populations, in terms of interactions, can influence structural stability, a robust measure of species' likelihood of persistence in mutualistic systems. Next, we examine how intraspecific variation in mutualistic interactions affects species' persistence theoretically in a simplified community, which provides a solid foundation for contextualizing empirical results. This theoretical exploration revealed that differences in the benefits received by different individual types by mutualistic partners, as driven by the way interactions are distributed among those types due to individual specialization, strongly influence species persistence. Building on these insights, we move beyond the theoretical framework and work through an empirical case study involving three co-occurring plant species. Drawing from detailed field data on plant–pollinator interactions and plant fitness, we quantify intraspecific variation in the mutualistic benefits received by plants and incorporate this variation into estimations of structural stability. Through explicit consideration of this facet of intraspecific variation, we found that, for all three focal plant species, populations composed of individuals specialized in pollinator use promote the persistence of the plant species they belong to and their associated pollinator community, only in the absence of heterospecific plant competitors. However, more importantly, these positive effects do not hold when plant species compete with a broader, diverse plant community. In this case, two of the focal plant populations are more vulnerable when they comprise more specialized individuals and therefore are less likely to persist. By integrating the proposed theoretical approach with empirical data, this study highlights the importance of individual variation in promoting species persistence in mutualistic systems. In doing so, it not only advances our understanding of basic mechanisms that foster biodiversity maintenance but also provides practical insights for biodiversity conservation in the face of changing environmental conditions., Blanca Arroyo-Correa received funding from the Ministry of Universities of the Spanish Government (FPU19/02552 and EST23/00036) and a project grant from the Spanish Association of Terrestrial Ecology (AEET). Blanca Arroyo-Correa and Pedro Jordano were supported by grants CGL2017-82847-P and PID2022-136812NB-I00, funded by MCIN/AEI/10.13039/501100011033 and by the “European Union NextGenerationEU/PRTR”, grant P20-00736 from Junta de Andalucía, and a LifeWatch ERIC-SUMHAL project (LIFEWATCH-2019-09-CSIC-13), with FEDER-EU funding. E. Fernando Cagua acknowledges the support from the University of Canterbury Doctoral Scholarship, the Meadow Mushrooms Ltd.: University of Canterbury Postgraduate Scholarship, and a Education New Zealand: New Zealand Doctoral Research Scholarship. Daniel B. Stouffer acknowledges the support of a Rutherford Discovery Fellowship (RDF-13-UOC-003), administered by the Royal Society of New Zealand Te Apārangi., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Phage Therapy for Bone and Joint Infections: Towards Clinical Translation

  • Ortiz-Cartagena, Concha
  • Blasco, Lucía
  • Bleriot, Inés
  • Esteban, Jaime
  • Toro, María Dolores del
  • Pozo, José Luis del
  • Tomás, María
This article belongs to the Special Issue Bone and Joint Infections: The Challenges of Prevention, Diagnosis and Treatment and Opportunities for Future Research., Osteoarticular infections (OAIs), including osteomyelitis, septic arthritis, prosthetic joint infections, and facture-related infections, remain a major challenge due to biofilm formation and the prevalence of multidrug-resistant (MDR) pathogens. Although OAIs are predominantly caused by Staphylococcus aureus and coagulase-negative staphylococci, the increasing incidence of MDR Gram-negative infections adds further complexity to their management. Standard approaches, combining surgery and prolonged antibiotic therapy, frequently result in recurrence and poor outcomes. Bacteriophage (phage) therapy has emerged as a promising adjunct or alternative approach, offering high host specificity, replication at the infection site, and activity against biofilm-embedded bacteria. This review highlights recent advances in phage therapy for OAIs, focusing on administration routes (intravenous, intra-articular, topical, and oral) and on novel pharmaceutical delivery systems such as hydrogels, bone cements, microparticles, nanoparticles, and implant coatings. Preclinical and early clinical studies have analyzed phage stability, controlled release, and the synergistic effects of combined phage/antibiotic therapy. However, challenges remain regarding standardization, immunogenicity, and regulatory approval. Nonetheless, phage therapy shows promise for clinical translation as an adjunct or alternative to conventional treatments for OAIs. Well-designed clinical trials are urgently needed to confirm the efficacy of phage therapy, optimize delivery strategies, and integrate the treatments in routine practice. Despite encouraging outcomes for a successful clinical implementation, regulation and standardization of GMP production are required., This study was funded by grant PI22/00323 awarded to M. Tomás and PI awarded to Rafael Cantón PI19/01043 within the State Plan for R + D + I 2013–2016 (National Plan for Scientific Research, Technological Development and Innovation 2008–2011) and co-financed by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research-European Regional Development Fund “A Way of Making Europe” and Instituto de Salud Carlos III FEDER, CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III FEDER, and by a grant from the Instituto de Salud Carlos III (MePRAM Project, PMP22/00092 and COOPERA Project, COOP24CIII/00009), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, funded by NextGeneration European Union funds that support the actions of the Resilience and Recovery Facility., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Review : Hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19)

  • Pastick, Katelyn A.
  • Okafor, Elizabeth C.
  • Wang, Fan
  • Lofgren, Sarah M.
  • Skipper, Caleb P.
  • Nicol, Melanie R.
  • Pullen, Matthew F.
  • Rajasingham, Radha
  • McDonald, Emily G.
  • Lee, Todd C.
  • Schwartz, Ilan S.
  • Kelly, Lauren E.
  • Lother, Sylvain A.
  • Mitjà, Oriol|||0000-0003-3266-8868
  • Letang, Emili
  • Abassi, Mahsa
  • Boulware, David R.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical trials, uncontrolled case series, and public figure endorsements. While there is a growing body of scientific data, there is also concern for harm, particularly QTc prolongation and cardiac arrhythmias. Here, we perform a rapid narrative review and discuss the strengths and limitations of existing in vitro and clinical studies. We call for additional randomized controlled trial evidence prior to the widespread incorporation of hydroxychloroquine and chloroquine into national and international treatment guidelines.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Preclinical research in glycogen storage diseases, a comprehensive review of current animal models

  • Almodóvar Payá, Aitana|||0000-0002-1650-2908
  • Villarreal-Salazar, Mónica|||0000-0002-8794-691X
  • Luna Salva, Noemí de|||0000-0002-4342-794X
  • Nogales, Gisela|||0000-0002-7414-212X
  • Real-Martinez, Alberto|||0000-0002-4703-5142
  • Andreu Périz, Antoni Lluís
  • Martín, Miguel A.|||0000-0003-4741-772X
  • Arenas, Joaquín|||0000-0002-2877-5049
  • Lucia, Alejandro|||0000-0002-3025-2060
  • Vissing, John|||0000-0001-6144-8544
  • Krag, Thomas|||0000-0001-9330-668X
  • Pinós Figueras, Tomàs|||0000-0002-4379-0917
GSD are a group of disorders characterized by a defect in gene expression of specific enzymes involved in glycogen breakdown or synthesis, commonly resulting in the accumulation of glycogen in various tissues (primarily the liver and skeletal muscle). Several different GSD animal models have been found to naturally present spontaneous mutations and others have been developed and characterized in order to further understand the physiopathology of these diseases and as a useful tool to evaluate potential therapeutic strategies. In the present work we have reviewed a total of 42 different animal models of GSD, including 26 genetically modified mouse models, 15 naturally occurring models (encompassing quails, cats, dogs, sheep, cattle and horses), and one genetically modified zebrafish model. To our knowledge, this is the most complete list of GSD animal models ever reviewed. Importantly, when all these animal models are analyzed together, we can observe some common traits, as well as model specific differences, that would be overlooked if each model was only studied in the context of a given GSD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Endothelial damage, inflammation and immunity in chronic kidney disease

  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
  • Torramade-Moix, S.
  • Pascual, G.
  • Palomo, Marta|||0000-0002-3261-6577
  • Moreno-Castaño, Ana Belén|||0000-0003-0338-7514
  • Martínez Sánchez, Julia
  • Vera, M.
  • Cases Amenós, Aleix|||0000-0002-6962-8184
  • Escolar, Ginès
Chronic kidney disease (CKD) patients have an accelerated atherosclerosis, increased risk of thrombotic-ischemic complications, and excessive mortality rates when compared with the general population. There is also evidence of an endothelial damage in which the proinflammatory state, the enhanced oxidative stress, or the accumulation of toxins due to their reduced renal clearance in uremia play a role. Further, there is evidence that uremic endothelial cells are both involved in and victims of the activation of the innate immunity. Uremic endothelial cells produce danger associated molecular patterns (DAMPS), which by binding to specific pattern recognition receptors expressed in multiple cells, including endothelial cells, induce the expression of adhesion molecules, the production of proinflammatory cytokines and an enhanced production of reactive oxygen species in endothelial cells, which constitute a link between immunity and inflammation. The connection between endothelial damage, inflammation and defective immunity in uremia will be reviewed here.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

A systematic review and realist synthesis on toilet paper hoarding, COVID or not COVID, that is the question

  • Labad, Javier|||0000-0003-2214-1886
  • González-Rodríguez, Alexandre|||0000-0003-1855-8566
  • Cobo Gomez, Jesus Vicente|||0000-0002-2032-9343
  • Puntí Vidal, Joaquim|||0000-0001-6572-3398
  • Farré Martí, Josep Maria|||0000-0002-0702-7922
To explore whether the coronavirus disease 2019 (COVID-19) pandemic is associated with toilet paper hoarding and to assess which risk factors are associated with the risk of toilet paper hoarding. A systematic review and realist review were conducted. PubMed, Web of Science, Scopus and PsycINFO were searched (systematic review). PubMed, pre-prints and grey literature were also searched (realist review). The databases were searched from inception until October 2020. There were no restrictions on the study design. For the systematic review, toilet paper hoarding was the main outcome, and pathological use of toilet paper was the secondary outcome. For the realist review, the context-mechanisms-outcome (CMO) scheme included the COVID-19 pandemic (context), four proposed mechanisms, and one outcome (toilet paper hoarding). The four potential mechanisms were (1) gastrointestinal mechanisms of COVID-19 (e.g. diarrhoea), (2) social cognitive biases, (3) stress-related factors (mental illnesses, personality traits) and (4) cultural aspects (e.g. differences between countries). All studies of human populations were considered (including general population studies and clinical studies of patients suffering from mental health problems). The systematic review identified 14 studies (eight studies for the main outcome, six studies for the secondary outcome). Three surveys identified the role of the COVID-19 threat in toilet paper hoarding in the general population. One study pointed to an association between a personality trait (conscientiousness) and toilet paper buying and stockpiling as well as an additional significant indirect effect of emotionality through the perceived threat of COVID-19 on toilet paper buying and stockpiling. Six case reports of pathological use of toilet paper were also identified, although none of them were associated with the COVID-19 pandemic. The realist review suggested that of all the mechanisms, social cognitive biases and a bandwagon effect were potential contributors to toilet paper hoarding in the general population. The stressful situation (COVID-19 pandemic) and some personality traits (conscientiousness) were found to be associated with toilet paper hoarding. Cultural differences were also identified, with relatively substantial effects of toilet paper hoarding in several Asian regions (Australia, Japan, Taiwan and Singapore). The COVID-19 pandemic has been associated with a worldwide increase in toilet paper hoarding. Social media and social cognitive biases are major contributors and might explain some differences in toilet paper hoarding between countries. Other mental health-related factors, such as the stressful situation of the COVID-19 pandemic, fear of contagion, or particular personality traits (conscientiousness), are likely to be involved. PROSPERO CRD42020182308.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Transitioning From Preclinical Evidence to Advanced Therapy Medicinal Product, A Spanish Experience

  • Gastelurrutia, Paloma|||0000-0001-6974-9210
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Vives Armengol, Joaquim|||0000-0001-9719-5235
  • Coll-Bonet, Ruth|||0000-0003-0174-379X
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
A systematic and ordered product development program, in compliance with current quality and regulatory standards, increases the likelihood of yielding a successful advanced therapy medicinal product (ATMP) for clinical use as safe and effective therapy. As this is a novel field, little accurate information is available regarding the steps to be followed, and the information to be produced to support the development and use of an ATMP. Notably, successful clinical translation can be somewhat cumbersome for academic researchers. In this article, we have provided a summary of the available information, supported by our experience in Spain throughout the development of an ATMP for myocardial infarction, from the pre-clinical stage to phase I clinical trial approval.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

SGLT2 inhibitors for non-diabetic kidney disease, drugs to treat CKD that also improve glycaemia

  • Fernández-Fernández, Beatriz
  • Sarafidis, Pantelis|||0000-0002-9174-4018
  • Kanbay, Mehmet|||0000-0002-1297-0675
  • Navarro-González, Juan F.|||0000-0002-5015-7474
  • Soler, María José|||0000-0003-3621-0766
  • Górriz, Jose Luis|||0000-0002-1134-9051
  • Ortiz, Alberto|||0000-0002-9805-9523
Sodium-glucose co-transporter-2 (SGLT2) inhibitors decreased cardiovascular (CV) events and improved renal outcomes in CV safety studies in type 2 diabetes melitus (T2DM) patients at high CV risk. Canagliflozin also improved kidney outcomes in diabetic kidney disease in the Canagliflozin and Renal Events in Diabetes and Nephropathy Clinical Evaluationtrial. More recently, the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial showed that dapagliflozin improved CV outcomes in patients with HF with or without diabetes. Protection from HF in non-diabetics was confirmed for empagliflozin in the EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced) trial. A meta-analysis of DAPA-HF and EMPEROR-Reduced confirmed reductions in all-cause and CV death and the combined risk of CV death or worsening HF, as well as in the composite renal endpoint {hazard ratio [HR] 0.62 [95% confidence interval (CI) 0.43-0.90]} without differences based on the presence of diabetes or baseline estimated glomerular filtration rate (eGFR). Moreover, the Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease (DAPA-CKD) showed that dapagliflozin as an add-on over renin-angiotensin system blockade in patients with chronic kidney disease (CKD; with or without T2DM) reduced the HR for the primary endpoint (time to the first occurrence of ≥50% eGFR decline, end-stage kidney disease or renal or CV death) to 0.61 (95% CI 0.51-0.72) and for the secondary endpoints of worsening renal function or death from kidney failure [HR 0.56 (95% CI 0.45-0.68)], hospitalization for HF or CV death [HR 0.71 (95% CI 0.55-0.92)] and all-cause mortality [HR 0.69 (95% CI 0.53-0.88)]. These beneficial effects were consistent in patients with and without T2DM. In conclusion, SGLT2 inhibitors offer CV and kidney protection in both diabetic and non-diabetic CKD and, additionally, improve glycaemic control in T2DM, making them first-line therapy for CKD independent from diabetic status.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

An evidence map of actigraphy studies exploring longitudinal associations between rest-activity rhythms and course and outcome of bipolar disorders

  • Scott, Jan
  • Colom, Francesc|||0000-0002-9516-9030
  • Young, Allan|||0000-0003-2291-6952
  • Bellivier, Frank
  • Etain, Bruno|||0000-0002-5377-1488
Evidence mapping is a structured approach used to synthesize the state-of-the-art in an emerging field of research when systematic reviews or meta-analyses are deemed inappropriate. We employed this strategy to summarise knowledge regarding longitudinal ecological monitoring of rest-activity rhythms (RAR) and disease modifiers, course of illness, treatment response or outcome in bipolar disorders (BD). We had two key aims: (1) to determine the number and type of actigraphy studies of in BD that explored data regarding: outcome over time (e.g. relapse/recurrence according to polarity, or recovery/remission), treatment response or illness trajectories and (2) to examine the range of actigraphy metrics that can be used to estimate disruptions of RAR and describe which individual circadian rhythm or sleep-wake cycle parameters are most consistently associated with outcome over time in BD. The mapping process incorporated four steps: clarifying the project focus, describing boundaries and 'coordinates' for mapping, searching the literature and producing a brief synopsis with summary charts of the key outputs. Twenty-seven independent studies (reported in 29 publications) were eligible for inclusion in the map. Most were small-scale, with the median sample size being 15 per study and median duration of actigraphy being about 7 days (range 1-210). Interestingly, 17 studies comprised wholly or partly of inpatients (63%). The available evidence indicated that a discrete number of RAR metrics are more consistently associated with transition between different phases of BD and/or may be predictive of longitudinal course of illness or treatment response. The metrics that show the most frequent associations represent markers of the amount, timing, or variability of RAR rather than the sleep quality metrics that are frequently targeted in contemporary studies of BD. Despite 50 years of research, use of actigraphy to assess RAR in longitudinal studies and examination of these metrics and treatment response, course and outcome of BD is under-investigated. This is in marked contrast to the extensive literature on case-control or cross-sectional studies of actigraphy, especially typical sleep analysis metrics in BD. However, given the encouraging findings on putative RAR markers, we recommend increased study of putative circadian phenotypes of BD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Hypoxia, the cornerstone of glioblastoma

  • Domènech Viñolas, Marta|||0000-0003-4827-9170
  • Hernández, Ainhoa|||0000-0003-4678-6662
  • Plaja, Andrea|||0000-0002-7862-9197
  • Martínez Balibrea, Eva|||0000-0002-4501-7100
  • Balañá, Carmen|||0000-0003-0771-0390
Glioblastoma is the most aggressive form of brain tumor in adults and is characterized by the presence of hypervascularization and necrosis, both caused by a hypoxic microenvironment. In this review, we highlight that hypoxia-induced factor 1 (HIF-1), the main factor activated by hypoxia, is an important driver of tumor progression in GB patients. HIF-1α is a transcription factor regulated by the presence or absence of O2. The expression of HIF-1 has been related to high-grade gliomas and aggressive tumor behavior. HIF-1 promotes tumor progression via the activation of angiogenesis, immunosuppression, and metabolic reprogramming, promoting cell invasion and survival. Moreover, in GB, HIF-1 is not solely modulated by oxygen but also by oncogenic signaling pathways, such as MAPK/ERK, p53, and PI3K/PTEN. Therefore, the inhibition of the hypoxia pathway could represent an important treatment alternative in a disease with very few therapy options. Here, we review the roles of HIF-1 in GB progression and the inhibitors that have been studied thus far, with the aim of shedding light on this devastating disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

The neurobiological basis of cognitive side effects of electroconvulsive therapy, a systematic review

  • Bassa, Adriana
  • Sagués, Teresa
  • Porta-Casteràs, Daniel|||0000-0002-3921-3607
  • Serra, Pilar
  • Martínez Amorós, Erika|||0000-0002-6718-7346
  • Palao, Diego|||0000-0002-3323-6568
  • Cano, Marta|||0000-0003-0675-9483
  • Cardoner, Narcís|||0000-0001-9633-0888
Decades of research have consistently demonstrated the efficacy of electroconvulsive therapy (ECT) for the treatment of major depressive disorder (MDD), but its clinical use remains somewhat restricted because of its cognitive side effects. The aim of this systematic review is to comprehensively summarize current evidence assessing potential biomarkers of ECT-related cognitive side effects. Based on our systematic search of human studies indexed in PubMed, Scopus, and Web of Knowledge, a total of 29 studies evaluating patients with MDD undergoing ECT were reviewed. Molecular biomarkers studies did not consistently identify concentration changes in plasma S-100 protein, neuron-specific enolase (NSE), or Aβ peptides significantly associated with cognitive performance after ECT. Importantly, these findings suggest that ECT-related cognitive side effects cannot be explained by mechanisms of neural cell damage. Notwithstanding, S-100b protein and Aβ40 peptide concentrations, as well as brain-derived neurotrophic factor (BDNF) polymorphisms, have been suggested as potential predictive biomarkers of cognitive dysfunction after ECT. In addition, recent advances in brain imaging have allowed us to identify ECT-induced volumetric and functional changes in several brain structures closely related to memory performance such as the hippocampus. We provide a preliminary framework to further evaluate neurobiological cognitive vulnerability profiles of patients with MDD treated with ECT.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Histone Modifications and Their Targeting in Lymphoid Malignancies

  • Fernández-Serrano, Miranda|||0000-0001-9040-8496
  • Winkler, René|||0000-0002-7570-0242
  • Santos, Juliana|||0000-0003-4148-9570
  • Le Pannérer, Marguerite Marie|||0000-0002-5779-8805
  • Buschbeck, Marcus|||0000-0002-3218-4567
  • Roué, Gaël|||0000-0003-0245-2257
In a wide range of lymphoid neoplasms, the process of malignant transformation is associated with somatic mutations in B cells that affect the epigenetic machinery. Consequential alterations in histone modifications contribute to disease-specific changes in the transcriptional program. Affected genes commonly play important roles in cell cycle regulation, apoptosis-inducing signal transduction, and DNA damage response, thus facilitating the emergence of malignant traits that impair immune surveillance and favor the emergence of different B-cell lymphoma subtypes. In the last two decades, the field has made a major effort to develop therapies that target these epigenetic alterations. In this review, we discuss which epigenetic alterations occur in B-cell non-Hodgkin lymphoma. Furthermore, we aim to present in a close to comprehensive manner the current state-of-the-art in the preclinical and clinical development of epigenetic drugs. We focus on therapeutic strategies interfering with histone methylation and acetylation as these are most advanced in being deployed from the bench-to-bedside and have the greatest potential to improve the prognosis of lymphoma patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis, New Insights From Biomarker Studies

  • Reyes-Leiva, David|||0000-0001-6983-7130
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Sirisi Dolcet, Sonia|||0000-0002-5366-7832
  • Cortés-Vicente, Elena|||0000-0002-1428-1072
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Luna Salva, Noemí de|||0000-0002-4342-794X
  • Blesa, Rafael|||0000-0003-4026-2884
  • Belbin, Olivia|||0000-0002-6109-6371
  • Montal, Victor|||0000-0002-5714-9282
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) lie at opposing ends of a clinical, genetic, and neuropathological continuum. In the last decade, it has become clear that cognitive and behavioral changes in patients with ALS are more frequent than previously recognized. Significantly, these non-motor features can impact the diagnosis, prognosis, and management of ALS. Partially overlapping neuropathological staging systems have been proposed to describe the distribution of TAR DNA-binding protein 43 (TDP-43) aggregates outside the corticospinal tract. However, the relationship between TDP-43 inclusions and neurodegeneration is not absolute and other pathophysiological processes, such as neuroinflammation (with a prominent role of microglia), cortical hyperexcitability, and synaptic dysfunction also play a central role in ALS pathophysiology. In the last decade, imaging and biofluid biomarker studies have revealed important insights into the pathophysiological underpinnings of extra-motor neurodegeneration in the ALS-FTLD continuum. In this review, we first summarize the clinical and pathophysiological correlates of extra-motor neurodegeneration in ALS. Next, we discuss the diagnostic and prognostic value of biomarkers in ALS and their potential to characterize extra-motor neurodegeneration. Finally, we debate about how biomarkers could improve the diagnosis and classification of ALS. Emerging imaging biomarkers of extra-motor neurodegeneration that enable the monitoring of disease progression are particularly promising. In addition, a growing arsenal of biofluid biomarkers linked to neurodegeneration and neuroinflammation are improving the diagnostic accuracy and identification of patients with a faster progression rate. The development and validation of biomarkers that detect the pathological aggregates of TDP-43 in vivo are notably expected to further elucidate the pathophysiological underpinnings of extra-motor neurodegeneration in ALS. Novel biomarkers tracking the different aspects of ALS pathophysiology are paving the way to precision medicine approaches in the ALS-FTLD continuum. These are essential steps to improve the diagnosis and staging of ALS and the design of clinical trials testing novel disease-modifying treatments.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Cardiovascular Disease in Type 1 Diabetes Mellitus, Epidemiology and Management of Cardiovascular Risk

  • Colom, Cristina|||0000-0002-2926-4697
  • Rull, Anna|||0000-0002-8907-7754
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Pérez, Antonio|||0000-0001-5528-1143
Cardiovascular disease (CVD) is a major cause of mortality in type 1 diabetes mellitus (T1DM) patients, and cardiovascular risk (CVR) remains high even in T1DM patients with good metabolic control. The underlying mechanisms remain poorly understood and known risk factors seem to operate differently in T1DM and type 2 diabetes mellitus (T2DM) patients. However, evidence of cardiovascular risk assessment and management in T1DM patients often is extrapolated from studies on T2DM patients or the general population. In this review, we examine the existing literature about the prevalence of clinical and subclinical CVD, as well as current knowledge about potential risk factors involved in the development and progression of atherosclerosis in T1DM patients. We also discuss current approaches to the stratification and therapeutic management of CVR in T1DM patients. Chronic hyperglycemia plays an important role, but it is likely that other potential factors are involved in increased atherosclerosis and CVD in T1DM patients. Evidence on the estimation of 10-year and lifetime risk of CVD, as well as the efficiency and age at which current cardiovascular medications should be initiated in young T1DM patients, is very limited and clearly insufficient to establish evidence-based therapeutic approaches to CVD management.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

NAD+-Increasing Strategies to Improve Cardiometabolic Health?

  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Canyelles, Marina|||0000-0002-0278-5337
  • Mauricio, Didac|||0000-0002-2868-0250
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Julve i Gil, Josep|||0000-0002-6531-2246
Depleted nicotinamide adenine dinucleotide (NAD+) is a common hallmark of metabolic disorders. Therefore, NAD+-increasing strategies have evolved as a potential therapeutic venue to combat cardiometabolic diseases. Several forms of vitamin B3, i.e., nicotinamide and nicotinamide mononucleotide, and especially nicotinamide riboside, have attracted most interest as potentially safe and efficacious candidates for NAD+ restoration. Herein, we dissected the characteristics of the latest clinical trials testing the therapeutic potential of different vitamin B3 molecules to improve cardiometabolic health, with a special focus on randomized, placebo-controlled clinical trials performed in the context of obesity or other pathologies, mainly linked to cardiovascular system and skeletal muscle functionality. The favorable outcomes via NAD+-increasing strategies found in the different studies were quite heterogeneous. NAD+-increasing interventions improved capacity to exercise, decreased blood pressure, increased the anti-inflammatory profile and insulin-stimulated glucose disposal, and reduced the fat-free mass. Except for the decreased blood pressure, the significant results did not include many hard clinical end points, such as decreases in weight, BMI, fasting glucose, or HbA1c percentage. However, the analyzed trials were short-term interventions. Overall, the accumulated clinical data can be interpreted as moderately promising. Additional and long-term studies will be needed to directly compare the doses and duration of treatments among different vitamin B3 regimes, as well as to define the type of patients, if any, that could benefit from these treatments. In this context, a major point of advancement in delineating future clinical trials would be to identify subjects with a recognized NAD+ deficiency using novel, appropriate biomarkers. Also, confirmation of gender-specific effect of NAD+-increasing treatments would be needed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Apolipoprotein and lrp1-based peptides as new therapeutic tools in atherosclerosis

  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Solanelles Curco, Angels
  • García Rodríguez, Jesús Eduardo|||0000-0002-7758-6789
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Benitez, Sonia|||0000-0003-3565-0743
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Apolipoprotein (Apo)-based mimetic peptides have been shown to reduce atherosclerosis. Most of the ApoC-II and ApoE mimetics exert anti-atherosclerotic effects by improving lipid profile. ApoC-II mimetics reverse hypertriglyceridemia and ApoE-based peptides such as Ac-hE18A-NH2 reduce cholesterol and triglyceride (TG) levels in humans. Conversely, other classes of ApoE and ApoA-I mimetic peptides and, more recently, ApoJ and LRP1-based peptides, exhibit several antiatherosclerotic actions in experimental models without influencing lipoprotein profile. These other mimetic peptides display at least one atheroprotective mechanism such as providing LDL stability against mechanical modification or conferring protection against the action of lipolytic enzymes inducing LDL aggregation in the arterial intima. Other anti-atherosclerotic effects exerted by these peptides also include protection against foam cell formation and inflammation, and induction of reverse cholesterol transport. Although the underlying mechanisms of action are still poorly described, the recent findings suggest that these mimetics could confer atheroprotection by favorably influencing lipoprotein function rather than lipoprotein levels. Despite the promising results obtained with peptide mimetics, the assessment of their stability, atheroprotective efficacy and tissue targeted delivery are issues currently under progress.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Genetic kidney diseases as an underrecognized cause of chronic kidney disease, the key role of international registry reports

  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Furlano, Monica|||0000-0003-1025-3901
  • Ortiz, Alberto|||0000-0002-9805-9523
  • Ars, Elisabet|||0000-0002-4118-4358
Inherited kidney diseases (IKDs) are among the leading causes of early-onset chronic kidney disease (CKD) and are responsible for at least 10-15% of cases of kidney replacement therapy (KRT) in adults. Paediatric nephrologists are very aware of the high prevalence of IKDs among their patients, but this is not the case for adult nephrologists. Recent publications have demonstrated that monogenic diseases account for a significant percentage of adult cases of CKD. A substantial number of these patients have received a non-specific/incorrect diagnosis or a diagnosis of CKD of unknown aetiology, which precludes correct treatment, follow-up and genetic counselling. There are a number of reasons why genetic kidney diseases are difficult to diagnose in adulthood: (i) adult nephrologists, in general, are not knowledgeable about IKDs; (ii) existence of atypical phenotypes; (iii) genetic testing is not universally available; (iv) family history is not always available or may be negative; (v) lack of knowledge of various genotype-phenotype relationships and (vi) conflicting interpretation of the pathogenicity of many sequence variants. Registries can contribute to visualize the burden of IKDs by regularly grouping all IKDs in their annual reports, as is done for glomerulonephritis or interstitial diseases, rather than reporting only cystic disease and hiding other IKDs under labels such as 'miscellaneous' or 'other'. Any effort to reduce the percentage of patients needing KRT with a diagnosis of 'nephropathy of unknown etiology' or an unspecific/incorrect diagnosis should be encouraged as a step towards precision nephrology. Genetic testing may be of value in this context but should not be used indiscriminately, but rather on the basis of a deep knowledge of IKDs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Progress in cardiac research, From rebooting cardiac regeneration to a complete cell atlas of the heart

  • Davidson, Sean M.|||0000-0001-5182-4980
  • Padró, Teresa|||0000-0003-1921-954X
  • Bollini, S.
  • Vilahur, Gemma|||0000-0002-2828-8873
  • Duncker, D.J.
  • Evans, P.C.|||0000-0001-7975-681X
  • Guzik, T.
  • Hoefer, I.E.
  • Waltenberger, J.
  • Wojta, J.
  • Weber, C.
We review some of the important discoveries and advances made in basic and translational cardiac research in 2020. For example, in the field of myocardial infarction (MI), new aspects of autophagy and the importance of eosinophils were described. Novel approaches, such as a glycocalyx mimetic, were used to improve cardiac recovery following MI. The strategy of 3D bio-printing was shown to allow the fabrication of a chambered cardiac organoid. The benefit of combining tissue engineering with paracrine therapy to heal injured myocardium is discussed. We highlight the importance of cell-to-cell communication, in particular, the relevance of extracellular vesicles, such as exosomes, which transport proteins, lipids, non-coding RNAs, and mRNAs and actively contribute to angiogenesis and myocardial regeneration. In this rapidly growing field, new strategies were developed to stimulate the release of reparative exosomes in ischaemic myocardium. Single-cell sequencing technology is causing a revolution in the study of transcriptional expression at cellular resolution, revealing unanticipated heterogeneity within cardiomyocytes, pericytes and fibroblasts, and revealing a unique subpopulation of cardiac fibroblasts. Several studies demonstrated that exosome- and non-coding RNA-mediated approaches can enhance human induced pluripotent stem cell (iPSC) viability and differentiation into mature cardiomyocytes. Important details of the mitochondrial Ca2+ uniporter and its relevance were elucidated. Novel aspects of cancer therapeutic-induced cardiotoxicity were described, such as the novel circular RNA circITCH, which may lead to novel treatments. Finally, we provide some insights into the effects of SARS-CoV-2 on the heart.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Tobacco control policies in the 21st century, achievements and open challenges

  • Peruga, Armando|||0000-0002-1138-3292
  • López Medina, María José|||0000-0003-4402-2239
  • Martínez, Cristina|||0000-0002-9368-1356
  • Fernández, Esteve|||0000-0003-4239-723X
Noncommunicable diseases (NCDs), including cancer, are responsible for almost 70% of all deaths worldwide. Tobacco use is a risk factor common to most NCDs. This article discusses tobacco control policies and highlights major achievements and open challenges to reduce smoking prevalence and attributable morbidity and mortality in the 21st century. The introduction of the WHO Framework Convention on Tobacco Control in 2005 has been a key achievement in the field and has already facilitated a drop in both smoking prevalence and exposure to secondhand smoke. Indicatively, the size of the worldwide population benefiting from at least one cost-effective tobacco control policy has quadrupled since 2007. In addition, plain cigarette packaging has been successfully introduced as a tobacco control policy, surmounting efforts of the tobacco industry to challenge this based on trade and investment law. Nevertheless, tobacco control still faces major challenges. Smoking prevalence needs to be further reduced in a rather expedited manner. Smoke-free environments should be extended, and the use of plain tobacco packaging with large pictorial health warnings for all tobacco products should be further promoted in some parts of the world. Some of these measures will require prompt determination and diligence. For example, bold political decisions are needed to significantly increase real prices of tobacco products through excise taxes, ban added ingredients that are currently used to increase the attractiveness of tobacco products and ban the tobacco industry's corporate social responsibility initiatives. Finally, the debate on harm reduction strategies for tobacco control still needs to be resolved.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Telephone-Delivered Interventions for Suicide Prevention in Schizophrenia and Related Disorders, A Systematic Review

  • Comendador Vázquez, Laura|||0000-0002-5221-4794
  • Cebrià, Ana Isabel|||0000-0002-2632-8130
  • Sanz Ruiz, Antoni|||0000-0002-7952-4477
  • Pérez Solà, Víctor|||0000-0002-5825-2337
  • Palao, Diego|||0000-0002-3323-6568
BACKGROUND: Suicide is a health problem among patients diagnosed with schizophrenia. Telehealth technology has become an emerging intervention that may offer opportunities to reach this at-risk group. However, to consider the implementation of telehealth systems in the prevention of suicidal behaviors in patients diagnosed with schizophrenia, a review of the evidence is required. The present aim was to explore the effectiveness of telephone-based suicide prevention programs among patients with schizophrenia and related disorders. METHODS: A bibliographic search was carried out in the PubMed, PsycInfo, Scopus and Web of Science electronic databases following PRISMA guidelines. Two reviewers performed the selection, data extraction and methodological quality assessment. A total of 352 articles were retrieved, of which five studies met the eligibility criteria. RESULTS: Globally, an adherence was observed ranging from 78 to 100%. Three studies reported a reduction in suicidal ideation and two studies showed a reduction in the risk of relapse observed in the intervention group compared to a control group. CONCLUSIONS: In accordance with the limited data available, the use of a telephone contact approach appears to be feasible and effective in schizophrenia patients with suicidal behaviors. The preliminary evidence also suggests that this system appears to reduce suicidal ideation. Further research is required to design evidence-based future interventions and to determine whether this approach can improve patient outcomes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Gut Microbiota-Derived TMAO, A Causal Factor Promoting Atherosclerotic Cardiovascular Disease?

  • Canyelles, Marina|||0000-0002-0278-5337
  • Borràs, Carla|||0000-0002-0998-7855
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
Trimethylamine-N-oxide (TMAO) is the main diet-induced metabolite produced by the gut microbiota, and it is mainly eliminated through renal excretion. TMAO has been correlated with an increased risk of atherosclerotic cardiovascular disease (ASCVD) and related complications, such as cardiovascular mortality or major adverse cardiovascular events (MACE). Meta-analyses have postulated that high circulating TMAO levels are associated with an increased risk of cardiovascular events and all-cause mortality, but the link between TMAO and CVD remains not fully consistent. The results of prospective studies vary depending on the target population and the outcome studied, and the adjustment for renal function tends to decrease or reverse the significant association between TMAO and the outcome studied, strongly suggesting that the association is substantially mediated by renal function. Importantly, one Mendelian randomization study did not find a significant association between genetically predicted higher TMAO levels and cardiometabolic disease, but another found a positive causal relationship between TMAO levels and systolic blood pressure, which-at least in part-could explain the link with renal function. The mechanisms by which TMAO can increase this risk are not clearly elucidated, but current evidence indicates that TMAO induces cholesterol metabolism alterations, inflammation, endothelial dysfunction, and platelet activation. Overall, there is no fully conclusive evidence that TMAO is a causal factor of ASCVD, and, especially, whether TMAO induces or just is a marker of hypertension and renal dysfunction requires further study.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Role of Biomarkers for the Diagnosis of Prion Diseases, A Narrative Review

  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Ruiz Barrio, Iñigo|||0000-0002-2015-5857
  • Zelaya, Maria Victoria|||0000-0002-3692-3515
  • Mendioroz, Maite|||0000-0002-4179-5781
Prion diseases are progressive and irreversible neurodegenerative disorders with a low incidence (1.5-2 cases per million per year). Genetic (10-15%), acquired (anecdotal) and sporadic (85%) forms of the disease have been described. The clinical spectrum of prion diseases is very varied, although the most common symptoms are rapidly progressive dementia, cerebellar ataxia and myoclonus. Mean life expectancy from the onset of symptoms is 6 months. There are currently diagnostic criteria based on clinical phenotype, as well as neuroimaging biomarkers (magnetic resonance imaging), neurophysiological tests (electroencephalogram and polysomnogram), and cerebrospinal fluid biomarkers (14-3-3 protein and real-time quaking-induced conversion (RT-QuIC)). The sensitivity and specificity of some of these tests (electroencephalogram and 14-3-3 protein) is under debate and the applicability of other tests, such as RT-QuIC, is not universal. However, the usefulness of these biomarkers beyond the most frequent prion disease, sporadic Creutzfeldt-Jakob disease, remains unclear. Therefore, research is being carried out on new, more efficient cerebrospinal fluid biomarkers (total tau, ratio total tau/phosphorylated tau and neurofilament light chain) and potential blood biomarkers (neurofilament light chain, among others) to try to universalize access to early diagnosis in the case of prion diseases.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Mechanisms Involved in Epileptogenesis in Alzheimer's Disease and Their Therapeutic Implications

  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Olmedo-Saura, Gonzalo|||0000-0003-4864-5548
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Fortea, Juan|||0000-0002-1340-638X
Epilepsy and Alzheimer's disease (AD) incidence increases with age. There are recip-rocal relationships between epilepsy and AD. Epilepsy is a risk factor for AD and, in turn, AD is an independent risk factor for developing epilepsy in old age, and abnormal AD biomarkers in PET and/or CSF are frequently found in late-onset epilepsies of unknown etiology. Accordingly, epilepsy and AD share pathophysiological processes, including neuronal hyperexcitability and an early excitatory-inhibitory dysregulation, leading to dysfunction in the inhibitory GABAergic and excitatory glutamatergic systems. Moreover, both β-amyloid and tau protein aggregates, the anato-mopathological hallmarks of AD, have proepileptic effects. Finally, these aggregates have been found in the resection material of refractory temporal lobe epilepsies, suggesting that epilepsy leads to amyloid and tau aggregates. Some epileptic syndromes, such as medial temporal lobe epilepsy, share structural and functional neuroimaging findings with AD, leading to overlapping symptomatology, such as episodic memory deficits and toxic synergistic effects. In this respect, the existence of epilepti-form activity and electroclinical seizures in AD appears to accelerate the progression of cognitive decline, and the presence of cognitive decline is much more prevalent in epileptic patients than in elderly patients without epilepsy. Notwithstanding their clinical significance, the diagnosis of clinical seizures in AD is a challenge. Most are focal and manifest with an altered level of consciousness without motor symptoms, and are often interpreted as cognitive fluctuations. Finally, despite the frequent association of epilepsy and AD dementia, there is a lack of clinical trials to guide the use of antiseizure medications (ASMs). There is also a potential role for ASMs to be used as disease-modifying drugs in AD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Peptides against Low Density Lipoprotein (LDL) Aggregation Inhibit Intracellular Cholesteryl Ester Loading and Proliferation of Pancreatic Tumor Cells

  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Martínez Bosch, Neus|||0000-0003-3596-0039
  • Manero-Rupérez, Noemí
  • Claudi, Lene
  • La Chica Lhoëst, María Teresa|||0000-0002-9070-5973
  • Soler Castany, Marta
  • Ros-Blanco, Lia
  • Navarro, Pilar|||0000-0003-4314-4584
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Dyslipidemia, metabolic disorders and/or obesity are postulated as risk factors for pancreatic ductal adenocarcinoma (PDAC). The majority of patients with these metabolic alterations have low density lipoproteins (LDLs) with increased susceptibility to become aggregated in the extracellular matrix (ECM). LDL aggregation can be efficiently inhibited by low-density lipoprotein receptor-related protein 1 (LRP1)-based peptides. The objectives of this work were: (i) to determine if aggregated LDLs affect the intracellular cholesteryl ester (CE)/free cholesterol (FC) ratio and/or the tumor pancreatic cell proliferation, using sphingomyelinase-modified LDL particles (Aggregated LDL, AgLDL); and (ii) to test whether LRP1-based peptides, highly efficient against LDL aggregation, can interfere in these processes. For this, we exposed human pancreatic cancer cell lines (PANC-1, RWP-1 and Capan-1) to native (nLDL) or AgLDLs in the absence or presence of LRP1-based peptides (DP3) or irrelevant peptides (IP321). Results of thin-layer chromatography (TLC) following lipid extraction indicate that AgLDLs induce a higher intracellular CE/FC ratio than nLDL, and that DP3 but not IP321 counteracts this effect. AgLDLs also increase PANC-1 cell proliferation, which is inhibited by the DP3 peptide. Our results indicate that AgLDL-induced intracellular CE accumulation plays a crucial role in the proliferation of pancreatic tumor cell lines. Peptides with anti-LDL aggregation properties may thus exhibit anti-tumor effects.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Genome-Wide Studies in Ischaemic Stroke, Are Genetics Only Useful for Finding Genes?

  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Muiño, Elena|||0000-0001-5839-7328
  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • Llucià-Carol, Laia|||0000-0002-7732-0665
  • Lledós, Miquel|||0000-0001-8832-789X
  • Martín-Campos, Jesús María|||0000-0003-0414-037X
  • Cullell, Natalia|||0000-0001-5118-1014
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
Ischaemic stroke is a complex disease with some degree of heritability. This means that heritability factors, such as genetics, could be risk factors for ischaemic stroke. The era of genome-wide studies has revealed some of these heritable risk factors, although the data generated by these studies may also be useful in other disciplines. Analysis of these data can be used to understand the biological mechanisms associated with stroke risk and stroke outcome, to determine the causality between stroke and other diseases without the need for expensive clinical trials, or to find potential drug targets with higher success rates than other strategies. In this review we will discuss several of the most relevant studies regarding the genetics of ischaemic stroke and the potential use of the data generated.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection

  • Moga, Esther|||0000-0003-4264-6910
  • Lynton-Pons, Elionor|||0000-0001-5375-7195
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
Two years after the appearance of the SARS-CoV-2 virus, the causal agent of the current global pandemic, it is time to analyze the evolution of the immune protection that infection and vaccination provide. Cellular immunity plays an important role in limiting disease severity and the resolution of infection. The early appearance, breadth and magnitude of SARS-CoV-2 specific T cell response has been correlated with disease severity and it has been thought that T cell responses may be sufficient to clear infection with minimal disease in COVID-19 patients with X-linked or autosomal recessive agammaglobulinemia. However, our knowledge of the phenotypic and functional diversity of CD8+ cytotoxic lymphocytes, CD4+ T helper cells, mucosal-associated invariant T (MAIT) cells and CD4+ T follicular helper (Tfh), which play a critical role in infection control as well as long-term protection, is still evolving. It has been described how CD8+ cytotoxic lymphocytes interrupt viral replication by secreting antiviral cytokines (IFN-γ and TNF-α) and directly killing infected cells, negatively correlating with stages of disease progression. In addition, CD4+ T helper cells have been reported to be key pieces, leading, coordinating and ultimately regulating antiviral immunity. For instance, in some more severe COVID-19 cases a dysregulated CD4+ T cell signature may contribute to the greater production of pro-inflammatory cytokines responsible for pathogenic inflammation. Here we discuss how cellular immunity is the axis around which the rest of the immune system components revolve, since it orchestrates and leads antiviral response by regulating the inflammatory cascade and, as a consequence, the innate immune system, as well as promoting a correct humoral response through CD4+ Tfh cells. This review also analyses the critical role of cellular immunity in modulating the development of high-affinity neutralizing antibodies and germinal center B cell differentiation in memory and long-lived antibody secreting cells. Finally, since there is currently a high percentage of vaccinated population and, in some cases, vaccine booster doses are even being administered in certain countries, we have also summarized newer approaches to long-lasting protective immunity and the cross-protection of cellular immune response against SARS-CoV-2.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Cancer metastasis under the magnifying glass of epigenetics and epitranscriptomics

  • Janin, Maxime|||0000-0003-1013-4128
  • Davalos, Veronica|||0000-0003-4077-5137
  • Esteller, M|||0000-0003-4490-6093
Most of the cancer-associated mortality and morbidity can be attributed to metastasis. The role of epigenetic and epitranscriptomic alterations in cancer origin and progression has been extensively demonstrated during the last years. Both regulations share similar mechanisms driven by DNA or RNA modifiers, namely writers, readers, and erasers; enzymes responsible of respectively introducing, recognizing, or removing the epigenetic or epitranscriptomic modifications. Epigenetic regulation is achieved by DNA methylation, histone modifications, non-coding RNAs, chromatin accessibility, and enhancer reprogramming. In parallel, regulation at RNA level, named epitranscriptomic, is driven by a wide diversity of chemical modifications in mostly all RNA molecules. These two-layer regulatory mechanisms are finely controlled in normal tissue, and dysregulations are associated with every hallmark of human cancer. In this review, we provide an overview of the current state of knowledge regarding epigenetic and epitranscriptomic alterations governing tumor metastasis, and compare pathways regulated at DNA or RNA levels to shed light on a possible epi-crosstalk in cancer metastasis. A deeper understanding on these mechanisms could have important clinical implications for the prevention of advanced malignancies and the management of the disseminated diseases. Additionally, as these epi-alterations can potentially be reversed by small molecules or inhibitors against epi-modifiers, novel therapeutic alternatives could be envisioned.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw

  • Calvete, Oriol|||0000-0002-2623-2876
  • Mestre, Julia|||0000-0002-4809-3897
  • Jerez, Andrés|||0000-0002-2079-6638
  • Sole, F|||0000-0002-3251-2161
There is a great deal of controversy in the hematologic community regarding the classification of secondary myelodysplastic neoplasms (MDSs). Current classifications are based on the presence of genetic predisposition and MDS post-cytotoxic therapy (MDS-pCT) etiologies. However, since these risk factors are not exclusive for secondary MDSs and there are multiple overlapping scenarios, a comprehensive and definitive classification is yet to come. In addition, a sporadic MDS might arise after a primary tumor fulfills the diagnostic criteria of MDS-pCT without a causative cytotoxicity. In this review, we describe the triggering pieces of a secondary MDS jigsaw: previous cytotoxic therapy, germline predisposition and clonal hematopoiesis. Epidemiological and translational efforts are needed to put these pieces together and ascertain the real weight of each of these pieces in each MDS patient. Future classifications must contribute to understanding the role of secondary MDS jigsaw pieces in different concomitant or independent clinical scenarios associated with the primary tumor.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

RHOA Therapeutic Targeting in Hematological Cancers

  • Santos, Juliana|||0000-0003-4148-9570
  • Profitós-Pelejà, Núria|||0000-0001-8923-6025
  • Sánchez Vinces, Salvador|||0000-0001-7041-6544
  • Roué, Gaël|||0000-0003-0245-2257
Primarily identified as an important regulator of cytoskeletal dynamics, the small GTPase Ras homolog gene family member A (RHOA) has been implicated in the transduction of signals regulating a broad range of cellular functions such as cell survival, migration, adhesion and proliferation. Deregulated activity of RHOA has been linked to the growth, progression and metastasis of various cancer types. Recent cancer genome-wide sequencing studies have unveiled both RHOA gain and loss-of-function mutations in primary leukemia/lymphoma, suggesting that this GTPase may exert tumor-promoting or tumor-suppressive functions depending on the cellular context. Based on these observations, RHOA signaling represents an attractive therapeutic target for the development of selective anticancer strategies. In this review, we will summarize the molecular mechanisms underlying RHOA GTPase functions in immune regulation and in the development of hematological neoplasms and will discuss the current strategies aimed at modulating RHOA functions in these diseases.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Recent advances in T-cell lymphoid neoplasms

  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Rodriguez-Sevilla, Juan José
  • Espinosa, Lluis|||0000-0002-2897-4099
  • Gallardo, Fernando|||0000-0002-8996-3828
T Cells comprise many subtypes of specified lymphocytes, and their differentiation and function take place in different tissues. This cellular diversity is also observed in the multiple ways T-cell transformation gives rise to a variety of T-cell neoplasms. This review covers the main types of T-cell malignancies and their specific characteristics, emphasizing recent advances at the cellular and molecular levels as well as differences and commonalities among them.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Endothelial activation and damage as a common pathological substrate in different pathologies and cell therapy complications

  • Palomo, Marta|||0000-0002-3261-6577
  • Moreno-Castaño, Ana Belén|||0000-0003-0338-7514
  • Salas, María Queralt|||0000-0003-4567-3682
  • Escribano Serrat, Silvia|||0000-0001-9499-8999
  • Rovira Argelagués, Montserrat|||0000-0001-7786-9079
  • Guillén-Olmos, Elena
  • Fernandez, Sara
  • Ventosa-Capell, Helena
  • Youssef, Lina|||0000-0002-0554-5507
  • Crispi, Fatima|||0000-0002-7422-5240
  • Nomdedeu, Meritxell
  • Martínez Sánchez, Julia
  • De Moner, Blanca
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
The endothelium is a biologically active interface with multiple functions, some of them common throughout the vascular tree, and others that depend on its anatomical location. Endothelial cells are continually exposed to cellular and humoral factors, and to all those elements (biological, chemical, or hemodynamic) that circulate in blood at a certain time. It can adapt to different stimuli but this capability may be lost if the stimuli are strong enough and/or persistent in time. If the endothelium loses its adaptability it may become dysfunctional, becoming a potential real danger to the host. Endothelial dysfunction is present in multiple clinical conditions, such as chronic kidney disease, obesity, major depression, pregnancy-related complications, septic syndromes, COVID-19, and thrombotic microangiopathies, among other pathologies, but also in association with cell therapies, such as hematopoietic stem cell transplantation and treatment with chimeric antigen receptor T cells. In these diverse conditions, evidence suggests that the presence and severity of endothelial dysfunction correlate with the severity of the associated disease. More importantly, endothelial dysfunction has a strong diagnostic and prognostic value for the development of critical complications that, although may differ according to the underlying disease, have a vascular background in common. Our multidisciplinary team of women has devoted many years to exploring the role of the endothelium in association with the mentioned diseases and conditions. Our research group has characterized some of the mechanisms and also proposed biomarkers of endothelial damage. A better knowledge would provide therapeutic strategies either to prevent or to treat endothelial dysfunction.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Peripheral immune aberrations in fibromyalgia, a systematic review, meta-analysis and meta-regression

  • Andrés Rodríguez, Laura|||0000-0001-5133-9811
  • Borràs, Xavier|||0000-0003-3972-1385
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Pérez-Aranda, Adrián|||0000-0002-1602-3413
  • Angarita-Osorio, Natalia|||0000-0001-8925-2754
  • Moreno-Peral, Patricia|||0000-0003-4130-9090
  • Montero-Marín, Jesús|||0000-0001-5677-1662
  • Garcia-Campayo, Javier|||0000-0002-3797-4218
  • Carvalho, André F.
  • Maes, Michael|||0000-0002-2012-871X
  • Luciano, Juan Vicente|||0000-0003-0750-1599
The objective was to identify immune alterations in patients with fibromyalgia syndrome (FMS) compared to healthy controls (HC) using meta-analysis and meta-regression. Six electronic databases were searched for suitable original articles investigating immune biomarkers in FMS in comparison to HC. We extracted outcomes and variables of interest, such as mean and SD of peripheral blood immune biomarkers, age or sex. A random-effects model with restricted maximum-likelihood estimator was used to compute effect sizes (standardized mean difference and 95% CI, Hedges' g) and meta-analysis, group meta-analysis and meta-regressions were conducted. Forty-three papers were included in this systematic review, of which 29 were suitable for meta-analysis. Interleukin (IL)-6 (g = 0.36 (0.09-0.63); I2 = 85.94; p = 0.01), IL-4 (g = 0.50 (0.03-0.98); I2 = 81.87; p = 0.04), and IL-17A (g = 0.53 (0.00-1.06); I2 = 87.15; p = 0.05), were significantly higher in FMS compared to HC while also combinations of cytokines into relevant phenotypes were significantly upregulated including M1 macrophage (g = 0.23 (0.03-0.43); I2 = 77.62; p = 0.02), and immune-regulatory (g = 0.40 (0.09-0.72); I2 = 84.81; p = 0.01) phenotypes. Heterogeneity levels were very high and subgroup and meta-regression analyses showed that many covariates explained part of the heterogeneity including medication washout, sex, time of blood sampling and exclusion of patients with major depressive disorder. In conclusion, FMS is accompanied by a disbalance between upregulated pro-inflammatory (M1 and Th-17) and immune-regulatory cytokines although effect sizes are small-to-moderate. Based on our results we provide specific methodological suggestions for future research, which should assess Th-1, Th-17, chemokines, and Th-2 phenotypes while controlling for possible confounding variables specified in this study.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Extracellular Vesicles as Drivers of Immunoinflammation in Atherothrombosis

  • Suades, Rosa|||0000-0002-0193-3115
  • Greco, Maria Francesca
  • Padró, Teresa|||0000-0003-1921-954X
  • Badimon, Lina|||0000-0002-9162-2459
Atherosclerotic cardiovascular disease is the leading cause of morbidity and mortality all over the world. Extracellular vesicles (EVs), small lipid-bilayer membrane vesicles released by most cellular types, exert pivotal and multifaceted roles in physiology and disease. Emerging evidence emphasizes the importance of EVs in intercellular communication processes with key effects on cell survival, endothelial homeostasis, inflammation, neoangiogenesis, and thrombosis. This review focuses on EVs as effective signaling molecules able to both derail vascular homeostasis and induce vascular dysfunction, inflammation, plaque progression, and thrombus formation as well as drive anti-inflammation, vascular repair, and atheroprotection. We provide a comprehensive and updated summary of the role of EVs in the development or regression of atherosclerotic lesions, highlighting the link between thrombosis and inflammation. Importantly, we also critically describe their potential clinical use as disease biomarkers or therapeutic agents in atherothrombosis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

New Insights into Treating Early and Advanced Stage Diabetic Retinopathy

  • Simó Canonge, Rafael|||0000-0003-0475-3096
  • Hernández, Cristina|||0000-0002-3109-1721
Diabetic retinopathy (DR) is the leading cause of preventable blindness in the working-age population. The disease progresses slowly, and we can roughly differentiate two stages: early-stage (ESDR), in which there are mild retinal lesions and visual acuity is generally preserved, and advanced-stage (ASDR), in which the structural lesions are significant and visual acuity is compromised. At present, there are no specific treatments for ESDR and the current recommended action is to optimize metabolic control and maintain close control of blood pressure. However, in the coming years, it is foreseeable that therapeutic strategies based in neuroprotection will be introduced in the clinical arena. This means that screening aimed at identifying patients in whom neuroprotective treatment might be beneficial will be crucial. Regarding the treatment of ASDR, the current primary course is based on laser photocoagulation and intravitreal injections of anti-angiogenic factors or corticosteroids. Repeated intravitreal injections of anti-VEGF agents as the first-line treatment would be replaced by more cost-effective and personalized treatments based on the results of "liquid biopsies" of aqueous humor. Finally, topical administration (i.e., eye drops) of neuroprotective, anti-inflammatory and anti-angiogenic agents will represent a revolution in the treatment of DR in the coming decade. In this article, all these approaches and others will be critically discussed from a holistic perspective.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Mechanisms modulating foam cell formation in the arterial intima, exploring new therapeutic opportunities in atherosclerosis

  • La Chica Lhoëst, María Teresa|||0000-0002-9070-5973
  • Martinez, A.
  • Claudi, Lene
  • Garcia, E.
  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Polishchuk, A.
  • Piñero, Janet|||0000-0003-1244-7654
  • Viladés Medel, David|||0000-0002-3638-9703
  • Guerra Ramos, José María|||0000-0001-5397-9177
  • Sanz, F.
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
In recent years, the role of macrophages as the primary cell type contributing to foam cell formation and atheroma plaque development has been widely acknowledged. However, it has been long recognized that diffuse intimal thickening (DIM), which precedes the formation of early fatty streaks in humans, primarily consists of lipid-loaded smooth muscle cells (SMCs) and their secreted proteoglycans. Recent studies have further supported the notion that SMCs constitute the majority of foam cells in advanced atherosclerotic plaques. Given that SMCs are a major component of the vascular wall, they serve as a significant source of microvesicles and exosomes, which have the potential to regulate the physiology of other vascular cells. Notably, more than half of the foam cells present in atherosclerotic lesions are of SMC origin. In this review, we describe several mechanisms underlying the formation of intimal foam-like cells in atherosclerotic plaques. Based on these mechanisms, we discuss novel therapeutic approaches that have been developed to regulate the generation of intimal foam-like cells. These innovative strategies hold promise for improving the management of atherosclerosis in the near future.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Impact of stress on brain morphology, Insights into structural biomarkers of stress-related disorders

  • Cardoner, Narcís|||0000-0001-9633-0888
  • Andero Galí, Raül|||0000-0003-3641-8903
  • Cano, Marta|||0000-0003-0675-9483
  • Marin Blasco, Ignacio Javier|||0000-0001-5096-2871
  • Porta-Casteràs, Daniel|||0000-0002-3921-3607
  • Serra Blasco, Maria|||0000-0001-5793-9906
  • Via, Esther|||0000-0002-2331-3232
  • Vicent Gil, Muriel|||0000-0001-7534-5095
  • Portella Moll, Maria J., 1975-|||0000-0002-2007-9516
Exposure to acute and chronic stress has a broad range of structural effects on the brain. The brain areas commonly targeted in the stress response models include the hippocampus, the amygdala, and the prefrontal cortex. Studies in patients suffering from the so-called stress-related disorders -embracing post-traumatic stress, major depressive and anxiety disorders- have fairly replicated animal models of stress response -particularly the neuroendocrine and the inflammatory models- by finding alterations in different brain areas, even in the early neurodevelopment. Therefore, this narrative review aims to provide an overview of structural neuroimaging findings and to discuss how these studies have contributed to our knowledge of variability in response to stress and the ulterior development of stress-related disorders. There are a gross number of studies available but neuroimaging research of stress-related disorders as a single category is still in its infancy. Although the available studies point at particular brain circuitries involved in stress and emotion regulation, the pathophysiology of these abnormalities -involving genetics, epigenetics and molecular pathways-, their relation to intraindividual stress responses -including personality characteristics, self-perception of stress conditions…-, and their potential involvement as biomarkers in diagnosis, treatment prescription and prognosis are discussed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Obesity-induced changes in cancer cells and their microenvironment, Mechanisms and therapeutic perspectives to manage dysregulated lipid metabolism

  • Lee-Rueckert, Miriam
  • Canyelles, Marina|||0000-0002-0278-5337
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Kovanen, Petri T.
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
Obesity has been closely related to cancer progression, recurrence, metastasis, and treatment resistance. We aim to review recent progress in the knowledge on the obese macroenvironment and the generated adipose tumor microenvironment (TME) inducing lipid metabolic dysregulation and their influence on carcinogenic processes. Visceral white adipose tissue expansion during obesity exerts systemic or macroenvironmental effects on tumor initiation, growth, and invasion by promoting inflammation, hyperinsulinemia, growth-factor release, and dyslipidemia. The dynamic relationship between cancer and stromal cells of the obese adipose TME is critical for cancer cell survival and proliferation as well. Experimental evidence shows that secreted paracrine signals from cancer cells can induce lipolysis in cancer-associated adipocytes, causing them to release free fatty acids and acquire a fibroblast-like phenotype. Such adipocyte delipidation and phenotypic change is accompanied by an increased secretion of cytokines by cancer-associated adipocytes and tumor-associated macrophages in the TME. Mechanistically, the availability of adipose TME free fatty acids and tumorigenic cytokines concomitant with the activation of angiogenic processes creates an environment that favors a shift in the cancer cells toward an aggressive phenotype associated with increased invasiveness. We conclude that restoring the aberrant metabolic alterations in the host macroenvironment and in adipose TME of obese subjects would be a therapeutic option to prevent cancer development. Several dietary, lipid-based, and oral antidiabetic pharmacological therapies could potentially prevent tumorigenic processes associated with the dysregulated lipid metabolism closely linked to obesity.